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Purpose: The purpose of this work was to evaluate the ability of a treatment delivery 
verification system to detect clinically significant mechanical errors in VMAT delivery utilizing 
data contained within a commercial record and verify (RV) system, and to test whether the 
system can be used to reconstruct dose distributions that agree more closely with measured dose 
distributions than do the original treatment plans. 
Methods:  VMAT treatment plans from five prostate patients, five head and neck patients, and 
five post-mastectomy chest wall patients treated at our clinic were selected for this study. Known 
mechanical errors were introduced into each plan, and the dosimetric effect of each error was 
evaluated by a radiation oncologist to determine mechanical error thresholds for clinical 
acceptability.  Next, shifted plans were delivered on an Elekta linear accelerator, and the 
resulting dose distribution was measured with a two-dimensional diode array. During delivery, 
positions of the gantry, multi-leaf collimator (MLC), and jaws were captured in both the RV 
system and the linac verification interface (LVI). Following plan delivery, recorded delivery data 
were analyzed to characterize the ability of the recording systems to recognize true mechanical 
error.  Finally, delivery parameters from both recording systems were imported to the treatment 
planning system and used to recalculate the dose delivered to the measurement phantom to test 
whether the system can be used to reconstruct dose distributions that agree more closely with 
measured dose distributions than do the original treatment plans. 
Results: Minimum mechanical error thresholds over all fifteen cases were found to be 1 mm for 
systematic MLC error, 2 mm for Gaussian-random MLC error, 3 mm for uniform-random MLC 
error, 3 mm for central leaf pair error and 2° for gantry error.  Analyzing delivery data yielded p-
values less than 0.05 for both RV and LVI systems for all central leaf pair and gantry shifts (1, 2, 
xviii 
 
and 3 mm central leaf pair shifts and 1, 2, 3, and 5° rotations), which means that each system 
could reliably detect errors at threshold values.  Reconstruction of delivery data by both RV and 
LVI systems failed to yield p-values less than 0.05 for prostate, head and neck, and chest wall 
cases. 
Conclusion: Both delivery verification systems examined were capable of detecting mechanical 
errors of 1 mm of the MLC and 2° of the gantry that produce clinically unacceptable changes in 
the planned dose distribution. However, dose reconstructed using the recorded delivery 
parameters showed no significant improvement in agreement with measured values. Thus, while 
the delivery verification system can detect mechanical errors, it cannot more accurately estimate 
the daily delivered dose than the original plans do. 
1 
 
Chapter 1: Introduction 
1.1 Conventional Intensity-Modulated Radiation Therapy (IMRT) 
1.1.1 Features of IMRT 
Over the past few decades, many technological improvements have been made in the field of 
radiation oncology. For example, intensity-modulated radiation therapy (IMRT), introduced in 
the early 1990s, is a radiation therapy technique in which nonuniform fluence is delivered to the 
patient from any given position of the treatment beam to optimize the composite dose 
distribution (Khan 2010). IMRT improves on the conventional technique by better conforming 
the dose distribution to the target volume, thereby minimizing healthy tissue irradiation (see 
Figure 1) (Teh, Woo and Butler 1999, Webb 2003) . These improvements are made possible by 
IMRT’s ability to create arbitrary field shapes with a multileaf collimator (MLC) and computer-
driven inverse planning strategies. 
 
Figure 1: Illustration of the difference between conventional radiotherapy (a) and IMRT (b).  In  
conventional radiotherapy, only rectangular fields can be achieved.  With IMRT the 





IMRT is achieved by utilizing a MLC to create conformal, modulated fields, which are 
typically delivered from five to nine fixed gantry angles chosen for optimal avoidance of critical 
structures and homogeneous dose distribution in the target volume. MLCs are composed of two 
banks of leaves, which can be individually positioned to create custom fields for specific target 
volumes. For our project, we used the Elekta MLCi2 (Elekta AB, Stockholm, Sweden). This 
MLC is composed of 95% tungsten with leaf thickness of 8.2 cm, and 3.26 mm leaf width 
(projected to 1 cm at isocenter).  The MLC consists of 80 leaves (40 per side) and is located in 
the treatment head, 32.6 cm from the source. To take full advantage of the MLC, inverse 
optimization algorithms are typically used to determine optimal combinations of leaf positions 
(called ‘segments’) based on dosimetric goals provided by the user. Each leaf segment covers 
part of the target volume, and the weighted summation of all segments at each gantry angle 
results in a nonuniform fluence pattern that, when combined with other beams, provides a 
composite uniform dose to the target volume while avoiding critical structures.  
Fixed-beam IMRT may be delivered with an MLC using two methods: segmental MLC 
(sMLC) or dynamic MLC (dMLC). In both cases, the radiation beam is turned off between 
gantry positions.  However, with sMLC (also called “step-and-shoot”), the segments are 
delivered in discrete steps, and the radiation beam is turned off between segments, allowing the 
leaves to move.  Each segment is one MLC configuration, and sMLC IMRT plans typically have 
around 10 segments per gantry angle.  dMLC does not use discrete segmentation for delivery and 
instead the MLC moves continuously while dose is delivered.  Figure 2 illustrates the differences 




Figure 2: Dynamic MLC (top) versus static-MLC (bottom). (Bortfeld, Schlegel, et al. 1999) 
 
1.1.2 Shortcomings of IMRT 
IMRT achieves its highly conformal dose delivery at the cost of time because of the 
discontinuous nature of the delivery and the large number of segments and beam angles.  A 
typical delivery consists of five to nine beam angles, each consisting of about ten or more 
segments.  Since the beam must be turned off between each segment for sMLC delivery, the 
delivery is interrupted between about 50 to 90 times for a typical plan.  For dMLC delivery, the 
beam is only interrupted once for each gantry angle.  Additionally, a larger number of monitor 
units (MU) must be delivered during IMRT as compared to conventional therapy to achieve 
similar doses since during IMRT much of the beam is attenuated by the MLC.   
Studies have compared dMLC and sMLC IMRT on the basis of plan quality, treatment time 
and MU usage.  Chui et al. (2001) found that dMLC and sMLC plan qualities were comparable 
for prostate, nasopharynx, and breast treatments but that sMLC required about 20% less MU and 
about twice the delivery time compared to dMLC.  Alaei et al. (2004) found sMLC deliveries to 
be about 15% longer and MU requirements about 15% fewer than dMLC deliveries for prostate 
and head and neck cases. 
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More recently, arc therapy techniques have been introduced which allow for significant 
reduction of treatment time.  
1.2 Volumetric Modulated Arc Therapy 
1.2.1 History of VMAT 
Intensity-Modulated Arc Therapy (IMAT) was first introduced in the 1990s (Yu 1995). 
IMAT incorporated continuous gantry motion in addition to dynamic MLC motion, which meant 
that treatments could be delivered without interruption from start to finish.  However, at that 
time, IMAT required multiple arcs (typically 3 to 5, but increasing with complexity of the plan) 
to deliver the desired dose distribution due to dose rate limitations. (Khan 2010). Additionally, 
IMAT was limited by a lack of commercial tools for planning and delivery.  In 2008, the concept 
of volumetric-modulated arc therapy (VMAT) was introduced, made possible by the 
development of more specialized tools for arc therapy planning and delivery. 
1.2.2 Features of VMAT 
In addition to utilizing a dynamic MLC and gantry approach like IMAT, VMAT delivery 
utilizes a variable dose rate. This additional degree of freedom greatly improves plan 
optimization over IMAT and, as a result, VMAT treatments can be delivered with fewer arcs 
(usually one or two). 
1.2.3 Comparison of VMAT vs. IMRT 
VMAT has been found to reduce treatment time and MU usage as compared to IMRT for a 
variety of sites (Fontenot, et al. 2011, Roa, et al. 2010, Lee, et al. 2011). Fontenot et al. (2011) 
found no statistically significant differences in target coverage, target homogeneity or normal 
tissue doses between VMAT and IMRT for prostate cancer treatments with seminal vesicle and 
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lymph node involvement.   They also noted a significant reduction in treatment time and MU 
usage in VMAT plans.  These improvements in efficiency are shown in Table 1. 
Table 1: IMRT vs. VMAT delivery efficiency (Fontenot, et al. 2011) 
Site Metric IMRT VMAT p-value 
Prostate + SV Monitor units 536 ± 131.8 467 ± 91.3  0.01 
Prostate + SV Delivery time (min) 9.5 ± 2.4 1.4 ± 0.1 <0.01 
Prostate + LN Monitor units 769.2 ± 116.9 435.2 ± 47.8  <0.01 
Prostate + LN Delivery time (min) 11.7 ± 1.3  1.4 ± 0.1 <0.01 
 
Rao et al. (2010) compared plan quality and efficiency for VMAT and IMRT plans in six 
lung, six prostate, and six head and neck cases.  They observed VMAT to achieve comparable 
plan quality to that of fixed-beam IMRT in terms of target coverage and critical structure 
sparing, while reducing MU usage and delivery time as shown in Table 2: IMRT vs. VMAT 
delivery efficiency  
Table 2: IMRT vs. VMAT delivery efficiency (Roa, et al. 2010) 
Site Metric IMRT VMAT 
Lung Monitor units 569 476  
Lung Delivery time (min) 7.9 2.1 
Prostate Monitor units 639 549 
Prostate Delivery time (min) 8.1 2.2 
Head and neck Monitor units 777 620 
Head and neck Delivery time (min) 11.1 4.6 
 
Lee et al. (2011) compared VMAT and 7-field IMRT plans for eighteen nasopharyngeal 
carcinoma treatments.  Again, VMAT was shown to be capable of producing treatment plans 
dosimetrically comparable to IMRT while improving on delivery efficiency as shown in Table 3. 
Table 3: Nasopharyngeal IMRT vs. VMAT delivery efficiency (Lee, et al. 2011) 
Site Metric IMRT VMAT p-value 
Nasopharynx Monitor units 602 ± 57 474 ± 48  <0.05 




A growing body of literature has indicated that significant improvements in efficiency can 
be made by using VMAT over IMRT, with no observable loss in plan quality. Such 
improvements are important for multiple reasons.  First, shorter treatment times can reduce the 
risk of internal organ motion during delivery (Kjaer-Kristoffersen, et al. 2009). A prolonged 
delivery time may also have an impact on treatment outcome, due to the increase in cell survival 
by recovery from sub lethal damage (Shibamoto, et al. 2004, Wang JZ, et al. 2003).  On a larger 
scale, fast treatments allow for greater clinical throughput – good for both the clinic and the 
public. Increasing MU efficiency is also advantageous for multiple reasons.  Decreasing monitor 
unit usage decreases both stray leakage and scatter dose to the patient, which may reduce the risk 
of secondary, out-of-field, cancers (Randall and Ibbott 2006, Dorr and Hermann 2002, Hall 
2006, Hall and Wuu 2003). Increasing MU efficiency may also reduce wear-and-tear on the 
treatment machine. 
While VMAT offers many attractive features, its delivery is inherently more complex than 
IMRT and depends on precise combinations of time-dependent mechanical parameters. As a 
result there is potential for delivery errors should any of its mechanisms fail.  Possible 
consequences of this delivery error include degradation of target dose and unfavorable increases 
in dose to healthy tissue. 
1.3 Current Knowledge 
1.3.1 Potential causes of VMAT delivery error  
LoSasso et al. (2008) investigated mechanical errors during sMLC and dMLC IMRT 
delivery.  Leaf positions were monitored by the Varian MLC software, which records positions 
at approximately 50 ms intervals.  Latency errors resulting from delays in the control loop were 
found in dynamic treatments related to MLC positions, with an average delay of 65 ms. For 
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dMLC deliveries, this latency caused leaves to lag behind their intended positions proportional to 
leaf speed and control loop delay. Furthermore, it was found that leaf speed can be affected by 
dirt and grease between the leaves providing differential sensitivity for individual leaves.  MLC 
errors can also be caused by gantry sag and thus are a function of the gantry position. Also, 
encoder drift in individual leaf motors may occur.  Oliver et al. (2010) reported that MLC error 
is a function of the gantry position and leaf speed and is different for each leaf pair. Other issues 
include optical reflector degradation, data transfer error, and electronic malfunction. 
1.3.2 Dosimetric effect of mechanical errors during VMAT delivery  
Mechanical positioning errors have an adverse effect on the dose received by the patient in 
all forms of radiotherapy delivery, including VMAT. Previous studies have shown that positional 
errors in mechanical delivery parameters during VMAT treatments can have deleterious effects 
on dose distributions.  Oliver et al. (2011) investigated the effect of random and systematic 
gantry position and MLC position errors by simulating offsets in ten prostate VMAT plans. 
Random, systematic, gap widening, and gap closing MLC errors of 0.5, 1, and 2 mm were 
simulated (Figure 3). 
For their analysis, Oliver et al. (2011) used generalized equivalent uniform dose (gEUD) to 
assess the magnitude of the dosimetric change resulting from the shifts.   gEUD is defined as the 
dose that, if uniformly distributed across the target, would provide the same tumor control as the 
actual nonuniform dose.  Results of the study are shown in Table 4. Values are given in % 
change gEUD per mm shift for the four different MLC shift types (random, systematic, gap close 





Figure 3: Random and systematic MLC shifts (Oliver M 2011), including (a) original unshifted 
plan, (Type 1) random MLC shift, (Type 2) systematic MLC shift, (Type 3a) systematic 
MLC close, and (Type 3b) systematic MLC open. 
 
Table 4: Prostate MLC shift gEUD sensitivity (Oliver, et al. 2010) 
Shift 
PTV Dose Sensitivity  
(%/mm) 
Bladder Dose Sensitivity  
(%/mm) 
Rectum Dose Sensitivity  
(%/mm) 
Random 0.191 0.387 0.261 
Systematic Shift -0.956 2.165 -0.777 
Systematic Close -7.160 -6.459 -7.067 
Systematic Open 8.183 10.897 10.31 
 
Systematic MLC shifts showed the largest impact on VMAT dose distributions. Random 
MLC errors of up to 2 mm were insignificant, but systematic MLC errors caused a gEUD 
decrease of approximately -1% dose/mm in the target volume.  Also, gap open and gap-close 
errors showed PTV gEUD dose sensitivity of 8.2% and -7.2% per mm, respectively. Gantry 
errors of 0.25°, 0.5°, and 1° were also simulated and found to be dosimetrically insignificant.  
Oliver et al. (2010) performed a similar study for eight head and neck treatments.  The same 
shifts were used, and gEUD was again used to quantify dosimetric effect.  Results of this study 
are shown in Table 5.  These values are dosimetric changes (in Gy) of the gEUD per mm of 
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MLC shift, including random, systematic, gap close and gap open MLC shifts for the primary 
PTV, the spinal cord and the glottic larynx. 
Table 5: Head and neck MLC shift gEUD sensitivity (Oliver, et al. 2010) 
Shift 
70Gy PTV Dose 
Sensitivity  
(Gy/mm) 
Spinal Cord Dose 
Sensitivity 
(Gy/mm) 
Glottic Larynx Dose 
Sensitivity 
(Gy/mm) 
Random -0.306 0.169 0.22 
Systematic Shift -3.582 0.570 0.35 
Systematic Close -6.473 -1.133 -1.7 
Systematic Open 1.858 2.311 2.55 
 
These findings agree with the prostate study.  Random MLC shifts showed little effect, 
while systematic MLC shifts and gap open/close shifts cause significant dosimetric effect in the 
PTV and critical structures. 
Tatsumi et al. (2011) investigated the impact of MLC position errors on measured dose 
distributions for five prostate patients, for plans created by three different treatment planning 
systems (Tatsumi, et al. 2011). Systematic single-bank MLC offsets ranging from 0 to ± 2.0 mm 
were applied to final plans by adjusting the linac controller. All deliveries were measured on a 
two-dimensional diode array, and comparisons were made between the nominal plan and all 
shifted plans. Subsets of typical leaf position patterns for VMAT plans from each TPS are shown 




Figure 4: Subset of typical leaf position patterns in VMAT delivery created by each TPS. 
(Tatsumi, et al. 2011) 
 
Measured dose distributions are compared with and without leaf position errors, and the 3% 
dose difference agreements are listed in Table 6.  As expected, larger MLC shifts result in 
decreased agreement between nominal and shifted delivery measurements. 
Table 6: MLC shift pass-rates at 3% dose difference level (Tatsumi, et al. 2011) 
Average pass rate for dose difference of 3% ± σ (%) 
Leaf offset (mm) Monaco SmartArc (Pinnacle) Ergo 
0 100 ± 0.0 100 ± 0.0 100 ± 0.0 
±0.3 100 ± 0.0 100 ± 0.0 100 ± 0.0 
±0.5 99.9 ± 0.2 100 ± 0.0 100 ± 0.0 
±0.8 97.4 ± 2.0 99.9 ± 0.3 100 ± 0.0 
±1.0 91.5 ± 5.1 98.7 ± 0.9 99.9 ± 0.3 
±1.5 68.4 ± 11.8 88.8 ± 5.9 98.7 ± 1.6 
±2.0 50.0 ± 12.7 73.9 ± 8.5 95.0 ± 2.9 
 
Action levels were defined as “the upper bound of the leaf position errors that can maintain 
the pass rate calculated by a dose comparison with and without errors under a dose difference 
criterion of 3%.”  Action levels of ±0.5 mm for Monaco (Elekta, USA), ±0.8 mm for SmartArc 
(Philips, USA) and ±1.5 mm for Ergo (Elekta, USA) were observed.  Interestingly, results varied 
widely between treatment planning systems.  Monaco plans were highly susceptible to MLC 
shifts (lower action level), whereas Ergo plans were relatively resilient (higher action level), 
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while SmartArc plans fell in the mid-range.  Difference in TPS sensitivity to MLC errors were 
correlated with leaf gap width, with smaller average leaf gap widths showing greater sensitivity 
to MLC changes.  This correlation means that any given MLC shift will have a relatively larger 
effect on a smaller field (quickly verifiable by comparing Figure 4 with Table 6.  This study was 
useful in demonstrating systematic MLC offset action levels (±0.8 mm for SmartArc) and 
correlating dosimetric error with average MLC gap width. 
These studies were useful in determining mechanical error action levels for creating 
observable differences in VMAT dose distributions. They also underscored the importance of 
mechanical positioning accuracy and the need to verify correct treatment delivery each fraction. 
1.3.3 Methods of VMAT delivery verification 
From the studies described above, we conclude that performance monitoring systems are a 
critical component to ensure the patient receives the intended dose on each fraction. Several such 
systems have been proposed.  
Several studies have described systems that monitor the positional accuracy of mechanical 
delivery parameters during VMAT delivery. Schreibmann et al. (2009) described a practical 
approach for patient-specific reconstruction of dose delivered during VMAT treatments using 
treatment controller log files for a Varian Trilogy linear accelerator. They analyzed delivery 
accuracy for five prostate patients using delivery logs extracted from the treatment console. 
These values were reimported to the treatment planning system and used to recalculate the dose 
in the patient planning CT.  They reported mean delivery errors of 0.15 mm and < 1° in the 
position of the MLC and gantry, respectively. They also reported differences between 
reconstructed and planned doses of less than 1.5% for all cases. One shortcoming of the study, 
however, was that it was limited to five prostate patients. Additionally, the process of acquiring 
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delivery logs requires manual extraction from the treatment control console, which may not be 
practical for routine use. 
More recently, Fontenot (2012) investigated the potential of a low-cost, automated daily 
delivery verification tool for VMAT treatment using data collected by the record and verify (RV) 
system. The RV-based system had the advantage of automated operation from remote terminals 
and was tested on 84 patients, including prostate, chest wall, abdomen and pelvis plans. The 
average percentage of MLC leaf positions within 3 mm, gantry positions within 2°, and jaw 
positions within 3 mm of planned positions was 92.9% ± 5.5%, 95.9% ± 2.9%, and 99.7% ± 
0.6%, respectively. However, differences were noted between mechanical delivery parameter 
positions reported by the RV-based system and values from log files extracted from the treatment 
control console. For example, the average MLC position error for a prostate patient was 0.38 ± 
0.03 mm and 0.13 ± 0.003 mm for the RV-based and treatment control systems, respectively, and 
1.48 ± 0.16 mm and 0.16 ± .01 mm for a chest wall patient   (J. Fontenot 2012). Subsequent 
investigation into these discrepancies revealed irregular reporting intervals for mechanical 
delivery parameters in the RV system, suggesting inferior performance monitoring compared 
with the treatment control system and potentially compromising the ability of the system to 
detect dosimetrically significant errors. 
1.4 Motivation 
Currently, a commercially-available automated VMAT delivery verification system does not 
exist. An ideal system would be capable of automatic extraction and analysis of delivery data and 
enable volumetric dose recalculation based on the extracted data.  It would also be established 
for use on any site for which VMAT treatment is utilized (prostate, head and neck, post-
mastectomy chest wall, lung, etc.).  The purpose of this project was to assess the ability of the 
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RV-based delivery verification system described by Fontenot (2012) to detect dosimetrically 
meaningful mechanical errors during VMAT treatments of prostate, head and neck and post-
mastectomy chest wall patients.  The overall goal was to establish a clinically useful QA system 
for automated VMAT delivery verification. 
 
1.5 Hypothesis and Specific Aims 
1.5.1 Hypothesis 
A treatment delivery verification system utilizing data contained within a commercial record 
and verify (RV) system can detect clinically significant mechanical errors in VMAT delivery and 
can be used to reconstruct dose distributions that agree more closely with measured dose 
distributions than do the original treatment plans.  This hypothesis was tested through the 
completion of three specific aims. 
1.5.2 Specific Aim 1: Determine mechanical parameter thresholds 
The purpose of Specific Aim 1 was to determine thresholds in the position of the MLC, 
jaw, and gantry beyond which an unacceptable dosimetric result is produced in VMAT plans for 
prostate, metastatic breast, and head and neck cancer patients.  By determining these thresholds 
for each site, we establish the accuracy needed by a delivery verification system for detecting 
mechanical error during VMAT delivery. 
1.5.3 Specific Aim 2: Characterize system ability to detect significant mechanical error 
The purpose of Specific Aim 2 was to characterize the ability of the RV-based delivery 
verification system to detect clinically significant mechanical errors during VMAT delivery, and 
to compare its results with values reported by the linac verification interface. 
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1.5.4 Specific Aim 3:  Compare dosimetric agreement of original and reconstructed plans 
The purpose of Specific Aim 3 was to compare measured dose distributions with dose 
distributions (a) computed from the original treatment plans, and (b) computed with mechanical 
delivery parameters from the delivery verification systems.  These comparisons were made for 
the purpose of external verification of the accuracy of the recording systems.  To further test the 
ability of the recording system, we also reconstructed and compared 3 mm systematic MLC 
shifted deliveries for three cases.  
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Chapter 2: Methods/Materials 
2.1 Aim 1 
“Determine thresholds in the position of the MLC, jaw, and gantry beyond which an 
unacceptable dosimetric result is produced in VMAT plans for prostate, head and neck, 
and metastatic breast cancer patients.” 
For this study, fifteen previously-treated VMAT plans were selected from our treatment 
planning system (Philips Pinnacle, Fitchburg WI).  To study a variety of plans, plans from three 
different treatment sites were obtained: five prostate, five head and neck, and five post-
mastectomy chest wall plans.  Plans were selected on the basis of prescription dose and number 
of arcs, and more recent plans were preferred (all within the last 2 years).  For prostate plans, a 
PTV dose of 76 Gy was required or 68 Gy for post-prostatectomy irradiation.  For head and neck 
plans, a three-tiered prescription dose of 70 or 66 Gy (high risk region), 63 or 60 Gy (lymph 
nodal region) and 58 or 56 Gy (low risk region) was required.  For chest wall plans, a 
prescription dose of approximately 50 or 50.4 Gy was required.  All head and neck and chest 
wall plans required two arcs, whereas prostate plans used either one or two arcs.  Because all 
plans were previously treated, optimization protocol, dose objectives and objective priorities 
were dictated by standard clinical planning procedure.  Specific treatment plan characteristics for 
each treatment site are outlined in Table 7, Table 8, and Table 9.  Simulated errors were inserted 
into the plan file using an in-house program, and “error thresholds” were determined by the 
judgement of a radiation oncologist based on evaluation of dose-volume-histograms (DVHs) and 
isodose distributions. Significant detriment to PTV dose or increases to critical structure doses, 
as determined by the radiation oncologist, would indicate clinically unacceptable plans. Error 
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thresholds were defined as minimum error values beyond which we would expect to see 
clinically unacceptable dose distributions.   
2.1.1 Prostate 
A typical prescription dose for a VMAT prostate patient at our clinic is 76 Gy in 38 fractions 
(or 68 Gy for a post-prostatectomy treatment).  Some VMAT prostate plans give a smaller 
prescription dose to the prostate bed and surrounding tissue with a boost to the prostate bed (46 
Gy with 32 Gy boost).  Typical organs at risk during VMAT prostate treatment include the 
rectum, bladder, urethra, and femoral heads. 
Table 7: Prostate treatment plan parameters 
Case # Prescription 
 (Gy) 
# Fractions # Arcs MU per Fraction 
(Arc 1 | Arc 2) 
Energy SmartArc 
Ɵ Resolution 
1 46 (+32) 23  2 346 | 305 6 MV 4° 
2 68 34 2 255 | 186 6 MV 4° 
3 76 38 1 499 6 MV 4° 
4 76  38 1 360 6 MV 4° 
5 76  38 2 217 | 209 6 MV 4° 
 
2.1.2 Head and neck 
All head and neck plans utilized a two-arc delivery (Table 8).  A typical VMAT head and 
neck treatment at our clinic utilizes a multi-tiered prescription dose approach, with the primary 
high-risk volume receiving 70 Gy in 35 fractions (or 66 Gy for post-operation), a secondary 
nodal volume receiving 63 Gy (60 Gy post-op), and a tertiary lower-risk volume receiving 56-58 
Gy. By reducing the prescription dose for secondary/tertiary target volumes, healthy tissue can 
be spared while still achieving adequate coverage.  Typical organs at risk during VMAT head 




Table 8: Head and neck treatment plan parameters 
Case # Prescription  (Gy) 
(1° | 2° | 3°) 
# Fractions # Arcs MU per Fraction 
(Arc 1 | Arc 2) 
Energy SmartArc 
Ɵ Resolution 
1 70 | 63 | 58 35 2 279 | 290 6 MV 4° 
2 70 | 63 | 56 35 2 269 | 243 6 MV 4° 
3 66 | 60 | 56 33 2 303 | 320 6 MV 4° 
4 70 | 63 | 58 35 2 261 | 268 6 MV 4° 
5 70 | 63 | 56 35 2 268 | 298 6 MV 4° 
 
2.1.3 Post-Mastectomy Chest Wall  
All post-mastectomy chest wall plans utilized a two partial-arc (~ 200° each) delivery (Table 
9).  Partial arcs are used because the treatments are relatively superficial; delivering dose from 
the posterior or contralateral side doesn’t add much coverage to the target volume and inevitably 
doses lungs and other critical structures.  A typical prescription dose for a VMAT chest wall 
patient at our clinic is 50.4 Gy in 28 fractions. By reducing the prescription dose for secondary 
target volumes, healthy tissue can be spared while still achieving adequate coverage.  
Table 9: Post-mastectomy chest wall treatment plan parameters 
Case # Prescription  (Gy) 
(1° | 2° | 3°) 
# Fractions # Arcs MU per Fraction 
(Arc 1 | Arc 2) 
Energy SmartArc 
Ɵ Resolution 
1 50.4 28 2 209 | 251 6 MV 4° 
2 50.4 28 2 141 | 246 6 MV 4° 
3 50.4 28 2 239 | 254 6 MV 4° 
4 50 25 2 294 | 209 6 MV 4° 
5 50 25 2 371 | 373 6 MV 4° 
 
2.1.4 Simulation of mechanical delivery errors 
Figure 5 illustrates the procedure for simulation of mechanical delivery errors.  Plans are 




Figure 5: Flowchart of Aim 1 methods.  The plan is (a) extracted from the treatment planning 
system, (b) modified using a Matlab script, and (c) reimported to the TPS. 
 
To determine the dosimetric impact of mechanical error, intentional errors of known 
magnitude were introduced into the fifteen selected VMAT plans.  Positioning errors of the MLC 
and gantry were examined. For each mechanical parameter, two types of errors were studied: 
systematic and random. Three types of systematic errors were examined: (1) all 80 MLC leaves 
and backup jaws were shifted by 1, 2, 3, 5, or 10 mm for all control points, (2) the central leaf 
pair of the MLC (leaves X1 21 and X2 21 as defined by the treatment planning system) was 
shifted by 1, 2, 3, 5, or 10 mm, and (3) the gantry was rotated by 1, 2, 3, 5, or 10° for all control 
points. MLC-shift plans were shifted in the positive X2 direction as defined by Pinnacle, and 
gantry-shift plans were shifted in the clockwise direction. Two types of random errors were 
examined, both of the MLC: (1) each of the 80 MLC leaves was randomly shifted, where the 
shift for each leaf was determined by randomly sampling from a Gaussian distribution with a 
mean of 0 and standard deviation of 1, 2, 3, 5, or 10 mm, and (2) each of the 80 MLC leaves was 
randomly shifted, where the shift for each leaf was determined by randomly sampling from a 
uniform distribution from 0 mm to a maximum shift of 1, 2, 3, 5,  or 10 mm. Illustrative 




Figure 6: MLC configurations for (a) a 10x10 cm2 nominal field, (b) systematic MLC shift, (c) 
central leaf pair shift, (d) uniformly-distributed random MLC shift, (e) Gaussian-
distributed random MLC shift, and (f) gantry shift. Vertical dashed lines indicate 
nominal MLC positions. 
 
Errors were introduced by exporting the beam data to text file, modifying the file, and then 
reimporting it back into the plan. A Pinnacle script (exportbeams.Script.p3rtp) was used to 
export the beam data to a text file. The text file contains all delivery information required for 
treatment, including gantry, MLC, x-ray jaw positions, and monitor unit weights for all control 
points.  The beam file was modified using an in-house MATLAB program.  Importation of the 
plan file was also facilitated by a script (importbeams.Script.p3rtp) within the treatment planning 
system.  The scripts can be found by navigating from the Pinnacle main menu to Utilities  





Figure 7: Pinnacle snapshot of plan file transportation 
 
2.1.5 Dose recalculation 
Dose was recomputed for all modified plans.  For each plan, the only modification made 
was the shift of interest.  To achieve this, beam weights and monitor units for modified plans 
were set equal to the values of the original plan in the prescription window (Figure 8).   
Additionally, CT-to-density tables, patient CT data, couch removal, isocenter position, dose grid, 
and region of interest contours were kept consistent with the original plan.  An adaptive convolve 
dose engine was used for computation with a 4 mm standard dose grid resolution.  In order to 
verify accurate extraction of plan data, original patient file DVHs and unmodified, reimported 




Figure 8: Pinnacle snapshot of monitor unit standardization 
 
The process was repeated over all error types and magnitudes, and the resulting plans were 
reviewed by a radiation oncologist to determine the minimum shift of each error type that 
produced a clinically unacceptable change in the planned dose distribution.  Plans were reviewed 
on the basis of dose-volume histograms and isodose plots, and clinical unacceptability was 
indicated by significant deterioration of PTV dose or significant increases in critical structure 
doses.  For each treatment site, an error threshold table was compiled 
Once all error thresholds were determined, the smallest (most conservative) values were 
taken as the final error thresholds.  Once this was completed for each treatment site, a final table 
was assembled with one error threshold per site per error type. These errors were used to 
determine the minimum mechnical error that the delivery verification system should be capable 
of detecting. 
2.2 Aim 2 
“Characterize the ability of the RV-based delivery verification system to detect clinically 
significant mechanical errors during VMAT delivery, and compare its results with values 
reported by the linac verification interface.” 
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The goal of Aim 2 was to characterize the ability of a delivery verification system based on 
record and verify (RV) system data to detect clinically significant mechanical errors during 
VMAT delivery, and to compare its results with values reported by the linac verification 
interface (LVI). To achieve this, select plans from Aim 1 were delivered on an Elekta Infinity 
linear accelerator system (Elekta AB, Stockholm, Sweden) at Mary Bird Perkins Cancer Center 
(MBPCC).  During delivery both the RV system and the LVI system recorded delivery 
parameters, and leaf and gantry errors were analyzed.  The usefulness of each system was 
determined based on its ability to reliably distinguish between erroneous and correct delivery.    
A simplified flowchart of Aim 2 methods is shown in Figure 9. 
 
Figure 9: Flowchart of Aim 2 methods 
 
2.2.1 Plan selection 
Two critical mechanical components to be assessed were the multi-leaf collimator (MLC) 
leaf positions and the treatment gantry angle.  Thus, we chose to deliver a set of systematic 
single-leaf shift plans and systematic gantry angle shift plans.  For each of the 15 cases selected 
in Aim 1, the 1, 2, and 3 mm systematic single-leaf shift plans and the 1, 2, 3, and 5 degree 
systematic gantry angle shift plans were chosen for delivery. Additionally, for three cases (one 
per site) the 1 mm systematic MLC shift was delivered.  These specific plans were selected to 
match Aim 1 errors, and larger magnitudes (5 mm MLC, 10 mm MLC, 20 mm MLC and 10° 
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gantry) were excluded because it was assumed they would be easily detectable. The plans were 
exported from the treatment planning system to “IMPAC_DCM_SCP” (Figure 10) and imported 
into the RV system using the “RTP Import” function in Mosaiq.  
 
Figure 10: Pinnacle snapshot of RT-file transfer to RV system 
 
2.2.2 Delivery and Recording 
Every 250 ms, the treatment control system records the complete machine state in a file.  At 
the conclusion of a treatment field, the file is temporarily available for download on a floppy 
drive until a new treatment field is initiated.  Additionally, MBPCC has two programs which 
receive machine-state information via the iCom-Vx protocol.  The RV system receives the iCom-
Vx data stream but only records the information at the beginning of each new segment.  For most 
clinical treatments at MBPCC, this corresponds to about one fourth of the iCom-Vx data.  Third 
party software extracts all the iCom-Vx data, which we refer to as the linac verification interface 
(LVI) data (FractionCHECK, Mobius Medical Systems, LP, Houston, TX).  The LVI records a 
total of about 200-300 data points per delivery, compared to 50-100 stored by the RV system.  
Reporting latencies between MU values and mechanical parameter positions were observed in 
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the LVI, and are therefore also present in the LV data.  Because monitor units were used for 
indexing mechanical delivery positions, the reporting latencies were difficult to quantify.  Leaf 
position errors of up to about 1 cm were observed, however, which would suggest the latencies 
are significant. 
2.2.3 Leaf error detection 
Because the data spacing of the reported positions did not match the planned position, the 
planned positions of the MLC, jaw, and gantry were interpolated on the basis of monitor units to 
match the indexing of each recording system. Leaf errors for each shifted leaf and gantry errors 
were calculated as the difference between the planned and delivered positions at the same MU.  
For systematic single-leaf plans, central leaves were shifted by the specified shift value for 
each control point while all other leaves remained as originally planned. Figure 11 shows an 
example leaf error per leaf plot, averaged over the entire delivery, reported by the RV system for 
prostate case #5 where the central leaf pair has been shifted by 1 mm.  Leaves 21 and 61 (X1 21 
and X2 21) are clearly distinguishable. 
 




Errors were classified as “detectable” if their value were significantly difference from zero 
at the 95% confidence level. Significance was determined using the Wilcoxon signed-rank test, 
which is a non-parametric statistical hypothesis test used to compare two samples that do not or 
cannot be verified to arise from normal distributions. We tested for a significant difference 
between delivery errors of leaves 21 and 61 reported by the system and zero; and if p was less 
than .05, then the error was classified as detectable by the verification system.  For two-arc 
deliveries, the total distribution included errors from both arcs.  Comparisons were performed in 
MATLAB using the “signrank” function.   
 To verify single leaf pair comparisons would be valid for analyzing systematic MLC 
errors, we also delivered 1 mm and 3 mm systematic MLC shifted plans for prostate case #5, 
head and neck case #5, chest wall case #5.  For each delivery, median errors for all in-field 
leaves (defined as the leaves between x-ray collimators for the entire delivery) were calculated.  
Again, for two-arc deliveries, the total distribution included errors from both arcs.  The range of 
in-field leaf error medians was reported, and we expected median systematic MLC errors to be 
consistent with median single-leaf errors.   
2.2.4 Gantry shift detection 
For gantry shifts, the gantry position was systematically offset from the planned angle by the 
desired shift value (1, 2, 3, and 5°) for all control points.  Again, data were collected and 
interpolated on the basis of monitor units to match the indexing of each recording system. Gantry 
errors were calculated as the difference between the planned and delivered positions at the same 
MU.  A Wilcoxon signed-rank test was applied to determine whether the distribution of gantry 
errors could be reliably distinguished from zero.  For two arc deliveries, the total distribution 
included gantry errors from both arcs. If p was less than 0.05, then we concluded the error was 
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detectable. Figure 12 shows an example of gantry error versus control point number reported by 
the RV system for a 1° gantry shift of prostate case #3.   
 
Figure 12: Prostate case #3 -- 1° gantry shift average gantry error plot. 
 
Finally, a table of minimum detectable leaf and gantry shifts was compiled.  If the minimum 
detectable shifts were less than the threshold values found in Aim 1, then we conclude that the 
delivery verification system can detect dosimetrically meaningful errors.  
2.3 Aim 3 
“Compare the agreement between measured dose distributions and dose distributions (a) 
from the original treatment plans and (b) reconstructed with mechanical delivery 
parameters from the delivery verification system.” 
The original treatment plans selected for Aim 1 were delivered to a two-dimensional diode 
array placed inside a solid water sleeve (MapCheck2 and MapPhantom, Sun Nuclear 
Corporation, Melbourne, FL) (Figure 13), and these measurements were compared against the 
planar dose calculated by the treatment planning system using (1) the original, planned 
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mechanical positions, (2) actual delivery parameters reported by the RV system, and (3) actual 
delivery parameters reported by the LVI. 
 
       
Figure 13: MapCHECK 2 device (left) and MapPHAN solid water phantom (right) 
 
2.3.1 Calculate planar dose profile on MapCheck phantom 
For each plan, measured doses were compared with planar doses calculated by the treatment 
planning system. Planar doses were computed in Pinnacle by copying the treatment beams onto 
the device to be used for measurements.  This was achieved in Pinnacle using by selecting 
“Patient Select” to QA Tools…  Copy To Phantom  MapPhan-MC2.header  Import (Figure 
14), which is a CT data of the diode array used for measurements in this work. The treatment 
beams were imported using the same script as described in Aim 1.  Beams were set to an 
isocenter of (-0.1, 0.0, 0.0), and standard dose-computation factors were applied as in Aim 1.  In 
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some chest wall cases, isocenter was located such that the phantom did not intercept the high 
dose region of the beam.  In these cases isocenter was shifted to include as much of the field as 
possible, and the phantom was shifted correspondingly.  
 
Figure 14: Pinnacle snapshot of phantom plan creation 
 
2.3.2 Deliver plans to MapCheck and record delivery (LVI and RV) 
For all fifteen cases, unmodified treatment plans were delivered and measured with the 
MapCHECK device.  Additionally, 3 mm systematic MLC shifted plans were delivered for 
prostate case #5, head and neck case #5, and chest wall case #5. Once delivery data were 
captured with either the RV or LVI system, data were interpolated to the planned monitor units 
spacing.  Thus, for the LVI, 200-300 data points were typically acquired for a single plan 
delivery, and were reduced to the number of original plan control points (89 for prostate and 
head and neck and typically 50-60 for chest wall).  For the RV system, control point samples 
were similarly interpolated to match the planned MU values (again, 89 for prostate and head and 
neck and typically 50-60 for chest wall).  The interpolated data derived from the delivery 
verification system data were then reimported to the treatment planning system, and the dose was 
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recalculated on the measurement geometry. Planar dose profiles were computed for the original 
and reconstructed plans on the phantom CT data in the same fashion as original plan profiles. 
2.3.3 Apply gamma analysis to quantify agreement  
Measured planar dose profiles were compared to calculated profiles from (1) the original 
plan, (2) the LVI-reconstructed plan, and (3) the RV-reconstructed plan. Figure 15 shows sample 
measured and calculated planar doses for prostate case #1. 
 
Figure 15: Isodose plots for one prostate treatment plan, with measured dose (a), original planar 
dose (b), RV-reconstructed planar dose (c), and LVI-reconstructed planar dose (d). 
 
Measured and calculated planar doses were compared using the gamma metric, originally 
proposed by Low et al. (1998), with agreement criteria of 3%/3mm and 2%/2mm dose 
difference/distance-to-agreement. Gamma analysis is a technique for comparing two data sets 
point-by-point that combines percent difference and distance to agreement.  For a point to pass, it 
must match the corresponding point on the second data set within the specified dose difference 
criteria OR there must be a point within the specified distance-to-agreement (3 or 2 mm) 
receiving the same dose.  If neither of these conditions can be met, the two comparisons are 




) is at a 
minimum. Agreement is quantified by the percentage of passing points, and agreements of 
interest are measurement vs. original plan, measurement vs. RV reconstructed plan, and 
30 
 
measurement vs. LVI-reconstructed plan.  For each treatment site, a table of these gamma pass 
rates were compiled.  Successful completion of this step requires consistently better agreement of 
the reconstructed dose with measured data. Differences were tested for statistical significance 
using the Wilcoxon signed-rank test. 
2.4 The Wilcoxon signed-rank test 
 In Aim 2, MLC delivery positions were compared with their planned positions for shifted 
leaf and gantry deliveries.  In Aim 3, the agreement between dose distributions reconstructed 
with delivery parameters from the RV and LVI systems and measured values were compared 
with the agreement between the planned and measured values. Generally, the Student’s t-test 
would be used to determine the significance of the difference between the data sets compared; 
however, this test requires that the values compared arise from normal distributions. The 
distributions in this work were tested for normality using the Kolgorov-Smirnov normality test, 
which showed that most of the distributions were not normally distributed.  Therefore, the 
Wilcoxon signed-rank test, which tests for differences between non-parametric distributions, was 
used to assess significance.  The limitations of the signed-rank test, however, are reduced 
statistical power and failure to account for the magnitude of differences between data sets. 
Instead, data from both data sets are simply ranked from least to greatest and a p-score is 
calculated by comparing the two sets of rankings.  
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Chapter 3: Results 
3.1 Aim 1 Results 
3.1.1 Impact of Mechanical Error on Treatment Plans 
For Aim 1, five error types were analyzed in each of the fifteen cases.  The error types 
include systematic MLC shifts, Gaussian-distributed random MLC shifts, uniformly-distributed 
random MLC shifts, systematic central leaf pair MLC shifts, and systematic gantry shifts.  For 
each error type, error magnitudes of 1, 2, 3, 5 and 10 mm (or degrees) were examined.  For 
random shifts, the Gaussian σ and the uniform-random maximum were set equal to 1, 2, 3, 5, and 
10 mm. The central leaf pair shifts also included a 20 mm shift since we expected this error type 
to produce less severe dosimetric effect.  For each modified plan, the resulting dose distribution 
was compared with the original treatment plan on the basis of isodose distributions and dose-
volume histograms (DVHs).  Section 3.1 describes the results by treatment site, and 
representative DVH and isodose plots are shown for each site.  Due to the large quantity of data, 
only a subset of data is shown and a complete set of DVH and isodose plots for all fifteen cases 
can be found in Appendix A.   
Prostate 
DVHs from prostate case #5 can be found in Figure 16. The DVHs shown are a clinically 
acceptable VMAT prostate plan (solid lines) and a modified plan (dashed lines) where all MLC 
leaves have been shifted by 1 cm in the positive X2 direction as defined by Pinnacle.  The plan 
with the systematic MLC shift of 1 cm degrades PTV (orange line) dose homogeneity and 
prescription dose coverage.  In addition, the rectum (brown line) and bladder (yellow line) doses 













Figure 17 shows isodose distributions for the original plan (left) and the plan with the 
systematic 1 cm MLC shift.  In the shifted plan, the 76Gy orange prescription line shrinks 
substantially and no longer covers the PTV.  In fact, the even the 75 and 70 Gy lines do not fully 
cover the PTV.  For these reasons, the the plan with the 1 cm systematic MLC for prostate case 
#5 was considered clinically unacceptable. 
Head and Neck 
DVHs from head and neck case #4 can be found in Figure 18. The DVHs shown are a 
clinically acceptable VMAT head and neck plan (solid lines) and a modified plan (dashed lines) 
where all MLC leaves have been uniform-randomly shifted with maximum shift of 1 cm. The 
plan with the 1 cm uniform-random shift degrades PTV (teal, light green and red lines) dose 
homogeneities and prescription dose coverage.  In addition, the left parotid (dark green line), 
right parotid (light green line), and spinal cord (blue line) doses are generally increased. 
Figure 19 shows isodose distributions for the original plan (left) and the plan with the 
uniform-random 1 cm MLC shift.  In the plan with the uniform-random 1 cm MLC shift, the 70 
Gy (red)  prescription line shrinks substantially and no longer covers the teal 70 Gy PTV.  The 
same is true for the 63 Gy (purple line, orange PTV) and 58 Gy (brown line, yellow PTV) 
prescription doses.  Additionally, the 35Gy (light blue) line covers more of the spinal cord.  For 
these reasons, the plan with the 1 cm uniform-random MLC shift for head and neck case #4 was 





Figure 18: Head and neck case #4 DVH comparison of original plan (solid) vs. 1 cm uniform-
random MLC shift (dashed) 
 
      
Figure 19: Head and neck case #5 isodose comparison of original plan (left) vs.10mm uniform-







Post-Mastectomy Chest Wall 
DVHs from chest wall case #2 can be found in  
Figure 20. The DVHs shown are a clinically acceptable VMAT chest wall plan (solid lines) 
and a modified plan (dashed lines) where the gantry was shifted by 5° in one direction for the 
entire delivery. The plan with the 5° gantry shift degrades PTV (blue line) dose homogeneity and 
prescription dose coverage.  In addition, the heart (pink line) and trachea (orange line) doses are 
generally increased.
 
Figure 20: Chest wall case #2 DVH comparison of original plan (solid) vs. 5° gantry shift  
(dashed) 
 
Figure 21 shows isodose distributions for the original plan (left) and the plan with the 5° 
gantry shift.  The 50.4 Gy (red)  prescription line shifts anteriorly and no longer covers the 
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posterior end of the PTV.  The lungs are mostly unaffected, and the heart (which is affected 
according to the DVH) is unfortunately not visible in this transverse slice.  Because of the 
degradation of PTV dose and increase in heart dose, the plan with the 5° gantry shift for head 
and neck case #2 was considered clinically unacceptable. 
      
Figure 21: Chest wall case #4 isodose comparison of original plan (left) vs. 5° gantry shift (right) 
 
3.1.2 Mechanical Error Thresholds 
The dosimetric changes produced by each error type and magnitude were reviewed by a 
radiation oncologist. The radiation oncologist selected the error threshold beyond which 
unacceptable changes were produced in the plan based on critical structure and PTV doses.  For 
each error type, the minimum acceptable error was taken as the threshold value. This means that 
any error greater than threshold would be expected to produce a clinically unacceptable dose 
distribution.   
There can be significant anatomical differences from one patient to the next, and differences 
in patient anatomy can lead to differences in treatment plan error susceptibility. There can be 
differences in critical structure proximity and shape, or PTV shape, size and position.  In cases 
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where critical structures are closer to the PTV or the PTV is more difficult to cover, plan quality 
may be more susceptible to mechanical error.  For example, if a patient is being treated for a 
tumor adjacent to the spinal cord, a slight shift in MLC position could result in a drastic and 
unacceptable increase in spinal cord dose. As a result of these differences in patient anatomy, 
there is variation in error threshold values, but by selecting the smallest threshold values we 
account for even the more sensitive cases. 
Prostate 
Table 10 shows error thresholds for each error type for prostate plans.  The table values 
indicate error values beyond which the radiation oncologist determined the dosimetric change to 
be clinically unacceptable.  For example, for prostate case #1, a threshold for the systematic 
MLC error was 1 mm, meaning that dose di,stribution including the 1 mm error was acceptable, 
but the dose distribution for the 2 mm error was not. Therefore, we conclude that systematic 
MLC errors beyond 1 mm would produce and unacceptable dosimetric change. Although 
mechanical errors of up to 10 mm or 10° were examined, some error types did not produce a 
dosimetrically unacceptable change over the entire range of values.  This occurred when the shift 
produced little effect in general, or when it produced negligible difference in the PTV and critical 
structure doses.  











Prostate 1 1 mm 2 mm 3 mm 5 mm 5° 
Prostate 2 2 mm 5 mm >10 mm 5 mm >10° 
Prostate 3 1 mm 5 mm 5 mm 5 mm 5° 
Prostate 4 3 mm 5 mm 5 mm 5 mm 5° 
Prostate 5 2 mm 3 mm 5 mm 5 mm >10° 




For prostate cases (Table 10), plans were found to be most sensitive to systematic MLC 
errors, resulting in smaller thresholds for that error type.  In most cases, Gaussian-random MLC 
shifts produced more of an effect than did uniform-random MLC shifts and therefore have lower 
thresholds.   Central leaf pair and gantry errors caused much less effect than systematic MLC 
bank shifts and resulted in larger thresholds.   
Head and Neck 











Neck 1 2 mm 3 mm 5 mm 3 mm 2° 
Neck 2 1 mm 3 mm 5 mm 3 mm 2° 
Neck 3 2 mm 3 mm 5 mm 5 mm 3° 
Neck 4 1 mm 3 mm 5 mm 3 mm 3° 
Neck 5 1 mm 3 mm 5 mm 5 mm 2° 
Minimum 1 mm 3 mm 5 mm  3 mm 2° 
 
For head and neck cases (Table 11), plans were again found to be most sensitive to 
systematic MLC errors.  Similar trends were seen with random-MLC shifts as in the prostate 
cases.  Sensitivity to central leaf pair errors was also about the same as in prostate cases. One 
significant difference between head and neck and prostate cases, however, was increased 
sensitivity to gantry positioning error for head and neck cases. The minimum head and neck 
gantry error threshold was 2°, whereas the minimum prostate gantry error threshold was 5°.  
Post-Mastectomy Chest Wall 
Chest wall thresholds showed similar trends as prostate and head and neck thresholds.  
Again, plans were most sensitive to systematic MLC error and thus these thresholds were lowest.  
Gaussian-random and uniform-random MLC errors yielded the same thresholds in all chest wall 
cases.  Chest wall plans showed little sensitivity to central leaf pair errors, and gantry error 
sensitivity was similar to head and neck cases. 
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Chest 1 5 mm 5 mm  5 mm 10 mm 3° 
Chest 2 3 mm 5 mm 5 mm 10 mm 3° 
Chest 3 3 mm 5 mm 5 mm 10 mm 5° 
Chest 4 5 mm 5 mm 5 mm 10 mm 3° 
Chest 5 3 mm 5 mm 5 mm 10 mm 5° 
Minimum 3 mm 5 mm 5 mm  10 mm 3° 
 
3.1.3 Minimum Mechanical Error Detectability Requirement 
The overall goal of this work was to develop a delivery verification system for routine 
clinical use. Such a system would therefore need to capable of detecting dosimetrically 
significant mechanical error for all patients and error types. Therefore, the smallest threshold 
values for MLC and gantry error were chosen as the minimum errors a delivery verification 
system would need to be capable of detecting.  











Prostate 1 mm 2 mm 3 mm  5 mm 5° 
Head and neck 1 mm 3 mm 5 mm  3 mm 2° 
Chest Wall 3 mm 5 mm 5 mm  10 mm 3° 
Global Minimum 1 mm 2 mm 3 mm 3 mm 2° 
 
The minimum threshold table, as expected, reflects the trends discussed earlier.  For each 
site systematic MLC error thresholds were lowest.  Based on this data, we conclude that an 
effective delivery verification system would need to be capable of detecting mechanical errors 
equal to the “global minimum” values listed in Table 13.  That is, That is, 1 mm MLC error and 





3.2 Aim 2 Results 
3.2.1 Formulate minimum detectable error tables (LVI and RV) 
The purpose of Aim 2 was to determine whether a RV or LVI-based delivery verification 
system could reliably resolve clinically significant mechanical delivery errors. The ability of 
each system (LVI and RV) to identify MLC and gantry errors was assessed for five prostate, five 
head and neck and five post-mastectomy chest wall plans. The errors assessed were 1, 2, and 3 
mm shifts of the MLC central leaf pair, the 1, 2, 3, and 5° gantry shifts, and 1 and 3 mm 
systematic MLC shifts.  Representative delivery error plots of these shifted plans for prostate, 
head and neck and chest wall cases are shown in the following sections.  Due to the large 
quantity of data, only a subset of data is presented here and a complete set of delivery error plots 
for all fifteen cases can be found in Appendix B.  Median, minimum, maximum, and Wilcoxon 
p-values for central leaf pair and gantry shift plan errors are shown in tables.  Additionally, tables 
containing MLC bank shift errors are included to demonstrate that leaf pair comparisons will be 
valid in cases where more than one leaf is erroneous. 
Prostate 
 




Figure 22 shows the average MLC leaf error recorded by the RV and LVI systems for a 
prostate plan where a 1 mm error has been introduced in central leaf pair (leaves #21 and 61). 
The y-axis shows the leaf error average over all control points, plotted against leaf.  By applying 
a signed-rank test to compare central leaf pair positions against planned positions as described 
earlier we can verify that the 1mm leaf error shift for prostate case #5 is detectable.  Table 14 and 
Table 15 show RV and LVI data, respectively, for median, minimum and maximum leaf errors 
along with signed-rank test p-values for the unshifted and 1, 2, and 3 mm central leaf pair shift 
prostate deliveries.  These errors compare leaf #21 and 61 recorded delivery positions against 
leaf #21 and 61 planned positions.  To conclude that shifts are detectable, p-values should be less 
than 0.05 and median errors should be close to the corresponding shift values. 
Table 14: Prostate unshifted and central leaf shift position error -- RV data (mm) 
 
Table 15: Prostate unshifted and central leaf shift position error -- LVI data (mm) 
 
Site Leaf # Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Prostate 1 Leaf 21 -0.16 -12.32 4.85 0.04 0.90 -8.27 7.87 0.00 1.76 -6.07 9.27 0.00 2.58 -6.30 14.91 0.00
Leaf 61 0.02 -7.84 5.82 0.90 1.10 -9.88 11.29 0.00 2.13 -4.92 9.05 0.00 3.10 -5.61 11.81 0.00
Prostate 2 Leaf 21 0.10 -5.42 8.87 0.41 0.90 -8.20 9.07 0.00 1.90 -8.93 9.88 0.00 2.99 -9.67 12.18 0.00
Leaf 61 0.10 -7.99 7.63 0.37 1.10 -7.03 8.87 0.00 2.10 -6.04 12.24 0.00 3.18 -7.75 14.09 0.00
Prostate 3 Leaf 21 -0.10 -6.17 7.90 0.92 0.90 -7.64 7.17 0.00 1.92 -4.80 9.83 0.00 2.90 -3.76 9.19 0.00
Leaf 61 0.20 -6.03 6.99 0.29 1.18 -8.30 8.89 0.00 2.10 -4.95 8.08 0.00 3.10 -6.57 9.54 0.00
Prostate 4 Leaf 21 -0.10 -2.05 0.67 0.11 0.90 -2.35 1.89 0.00 1.90 -1.27 2.66 0.00 2.90 -0.14 3.50 0.00
Leaf 61 0.10 -2.41 2.21 0.00 1.10 0.60 2.90 0.00 2.10 0.10 4.04 0.00 3.20 1.50 4.71 0.00
Prostate 5 Leaf 21 -0.10 -4.88 5.49 0.72 0.90 -6.60 9.25 0.00 1.90 -3.56 8.83 0.00 2.90 -2.51 7.74 0.00
Leaf 61 0.10 -8.97 6.79 0.29 1.10 -6.58 9.20 0.00 2.10 -7.38 11.00 0.00 3.10 -4.31 10.18 0.00
Unshifted 1mm Leaf Shift 2mm Leaf Shift 3mm Leaf Shift
Site Leaf # Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Prostate 1 Leaf 21 -0.10 -8.67 6.82 0.01 0.90 -8.27 7.87 0.00 1.78 -5.25 9.27 0.00 2.59 -6.30 14.91 0.00
Leaf 61 0.10 -9.25 8.46 0.02 1.10 -9.88 11.29 0.00 2.08 -9.87 9.84 0.00 3.10 -5.61 11.81 0.00
Prostate 2 Leaf 21 -0.10 -5.42 8.87 0.62 0.90 -8.20 9.07 0.00 1.93 -8.93 9.88 0.00 2.93 -9.67 12.18 0.00
Leaf 61 0.10 -7.99 7.63 0.91 1.10 -7.03 8.87 0.00 2.10 -6.04 12.24 0.00 3.11 -7.75 14.09 0.00
Prostate 3 Leaf 21 -0.07 -5.83 8.31 0.26 0.90 -7.64 7.17 0.00 1.90 -4.80 9.83 0.00 2.90 -3.76 9.19 0.00
Leaf 61 0.18 -9.33 6.70 0.00 1.13 -8.30 8.89 0.00 2.10 -4.95 8.08 0.00 3.10 -6.57 9.54 0.00
Prostate 4 Leaf 21 -0.10 -2.05 0.70 0.00 0.90 -2.35 1.89 0.00 1.90 -1.27 2.67 0.00 2.90 -0.14 3.50 0.00
Leaf 61 0.10 -2.41 2.21 0.00 1.10 0.26 2.90 0.00 2.10 0.10 4.04 0.00 3.20 1.50 4.79 0.00
Prostate 5 Leaf 21 -0.10 -4.88 5.49 0.01 0.90 -6.60 9.25 0.00 1.90 -3.56 8.83 0.00 2.90 -2.51 7.74 0.00
Leaf 61 0.10 -8.97 6.79 0.00 1.10 -6.58 9.20 0.00 2.10 -7.38 11.00 0.00 3.10 -4.31 10.18 0.00
2mm Leaf Shift 3mm Leaf ShiftUnshifted 1mm Leaf Shift
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P-values are less than 0.05 for all shifted leaves for both LVI and RV data and medians fall close 
to their expected values; therefore we accept the alternative hypothesis that shifted leaf positions 
are distinguishable from planned leaf positions at all offset values. For some cases (prostate #4 
and 5 –LVI and prostate #1 and 4—RV), however, the unshifted deliveries also show p-values 
less than 0.05.  This could be due to consistent latency error in the data resulting in a positive 
signed-rank test, despite median error values being close to zero.  Also, an interesting trend 
occurs in median leaf error values.  Leaf 21 error is consistently just below the expected value by 
about 0.1 mm and the opposing leaf 61 is consistently above the expected value by about 0.1 
mm.   
 Table 16 shows results for the prostate case #5 systematic MLC shifts.  Three shifts were 
examined: 0 mm, 1 mm and 3 mm.  For each delivery, in-field leaf errors were compiled and 
median leaf errors for each leaf were found.  Minimum, median, and maximums were calculated 
on the set of median leaf errors for each leaf bank (A and B).  These values are expected to be 
similar to the median errors found in the central leaf pair shifts. 
Table 16: Prostate case #5 systematic MLC shift, range of median leaf errors (mm).  LVI (left); 
RV (right). 
 
The table shows that median leaf errors were close to the expected values of 0 mm, 1 mm 
and 3 mm for the corresponding shifts, verifying that single leaf shift detection methods can be 
applied to erroneous leaf groups.  The trend mentioned above between leaves 21 and 61 is also 
seen in the systematic MLC shift deliveries, as Bank A median errors are about 0.1 mm less than 
Shift Bank Min Med Max
Unshifted Bank A -0.16 -0.10 -0.10
Bank B 0.10 0.10 0.10
1mm Shift Bank A 0.89 0.90 1.00
Bank B 1.05 1.10 1.20
3mm Shift Bank A 2.84 2.90 2.94
Bank B 3.10 3.10 3.20
Prostate 5 Systematic MLC shift error (mm) - RV
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expected and Bank B median errors are about 0.1 mm greater than expected. This discrepancy is 
seen throughout all treatment sites and for both systematic and central leaf pair shifts. 
Figure 23 shows prostate case #5, 2° gantry error for each control point plotted against 
control point number, with arcs 1 and 2 delineated by a dashed line. 
 
Figure 23: Prostate #5, 2° gantry error delivery.  RV (left) and LVI (right). 
 
For a perfect 2° gantry error delivery, gantry error values would be 2° for each control point.  
But due to mechanical error and recording uncertainty, there is a distribution of errors.  For this 
delivery, median gantry errors for the RV and LVI, respectively, were 2.04° and 2.01° with 
ranges -1.46 to 4.02° and -1.62 to 4.44°.  By applying the signed-rank test, we can verify that 
both the RV and LVI were capable of detecting a 2° systematic gantry error for prostate case #5. 
Table 17 (RV) and Table 18 (LVI) contain average gantry errors for all gantry shift prostate 
deliveries. Median errors correspond with shift values, and p-values for all shifted plans are less 
than 0.05; therefore these shifts are distinguishable.  Gantry error p-values for some unshifted 




Table 17: Prostate gantry shifts – RV gantry error and p-values (degrees) 
 
 
Table 18: Prostate gantry shifts – LVI gantry error and p-values (degrees) 
 
Table 19 contains resulting error detection values for both gantry and central leaf pair shifts. 
Table 19: Prostate error detection table 
Case Leaf (RV) Gantry (RV) Leaf (LVI) Gantry (LVI) 
Prostate 1 1 mm 1° 1 mm 1° 
Prostate 2 1 mm 1° 1 mm 1° 
Prostate 3 1 mm 1° 1 mm 1° 
Prostate 4 1 mm 1° 1 mm 1° 
Prostate 5 1 mm 1° 1 mm 1° 
Maximum 1 mm 1° 1 mm  1° 
 
We found that all prostate cases were capable of detecting the 1 mm central leaf pair shift 








Site Med Min Max p Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Prostate 1 -0.02 -3.76 2.46 0.08 0.90 -1.89 2.87 0.00 1.91 -0.71 3.96 0.00 2.92 0.01 4.77 0.00 4.89 2.12 6.99 0.00
Prostate 2 0.03 -1.87 1.47 0.78 1.01 -2.07 3.16 0.00 1.97 0.01 3.69 0.00 2.98 0.78 5.01 0.00 4.94 3.26 7.81 0.00
Prostate 3 0.17 -0.33 0.95 0.00 1.23 0.48 2.12 0.00 2.17 1.56 2.76 0.00 3.21 2.60 3.69 0.00 5.18 4.45 6.00 0.00
Prostate 4 0.17 -0.30 1.67 0.00 1.19 0.38 2.73 0.00 2.17 1.58 3.89 0.00 3.21 2.50 4.17 0.00 5.21 4.43 5.95 0.00
Prostate 5 -0.01 -3.81 2.62 0.82 1.01 -1.73 2.96 0.00 2.04 -1.46 4.02 0.00 3.03 -0.29 5.54 0.00 5.03 1.71 7.66 0.00
Unshifted 1° Gantry Shift 2° Gantry Shift 3° Gantry Shift 5° Gantry Shift
Site Med Min Max p Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Prostate 1 -0.08 -3.10 2.09 0.00 0.90 -1.91 2.87 0.00 1.92 -0.74 4.22 0.00 2.92 -0.08 4.77 0.00 4.90 2.04 6.99 0.00
Prostate 2 0.00 -1.87 2.00 0.83 1.01 -1.88 3.70 0.00 1.97 -0.71 3.49 0.00 2.98 0.20 4.73 0.00 4.95 2.09 6.78 0.00
Prostate 3 0.17 -0.50 0.85 0.00 1.21 0.43 2.12 0.00 2.16 1.28 2.88 0.00 3.20 2.47 3.99 0.00 5.17 4.21 6.01 0.00
Prostate 4 0.19 -0.77 1.69 0.00 1.19 0.20 2.75 0.00 2.20 1.50 3.89 0.00 3.19 2.30 4.17 0.00 5.16 4.40 6.12 0.00
Prostate 5 0.01 -3.81 2.84 0.81 1.05 -2.93 3.36 0.00 2.01 -1.62 4.44 0.00 3.01 -0.78 5.78 0.00 5.00 1.07 7.93 0.00
5° Gantry ShiftUnshifted 1° Gantry Shift 2° Gantry Shift 3° Gantry Shift
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Head and Neck 
   
Figure 24: Head and neck #5, 1mm central leaf error delivery.  RV (left) and LVI (right). 
 
Figure 24 shows the average MLC leaf error recorded by the RV and LVI systems for a head 
and neck plan where a 1 mm error has been introduced in central leaf pair (leaves #21 and 61). 
Table 20 and Table 21 show RV and LVI data, respectively, for median, minimum and 
maximum leaf errors and p-values for the unshifted and 1, 2, and 3 mm central leaf pair shift 
head and neck deliveries.  These errors compare leaf #21 and 61 recorded delivery positions 
against leaf #21 and 61 planned positions.   
Table 20: Head & neck unshifted and central leaf shift position error -- RV data (mm) 
 
Site Leaf # Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Neck 1 Leaf 21 -0.02 -8.54 9.43 0.87 0.99 -10.39 8.78 0.00 1.90 -7.72 10.05 0.00 3.16 -6.06 11.73 0.00
Leaf 61 0.05 -7.23 10.29 0.87 1.05 -10.09 9.45 0.00 2.00 -7.12 11.85 0.00 3.21 -7.89 12.91 0.00
Neck 2 Leaf 21 -0.13 -10.44 7.26 0.01 0.80 -10.02 7.73 0.00 1.90 -4.30 11.11 0.00 2.18 -5.03 9.68 0.00
Leaf 61 -0.07 -7.55 9.12 0.29 0.94 -8.82 7.73 0.00 2.00 -4.49 12.23 0.00 2.30 -5.29 11.48 0.00
Neck 3 Leaf 21 0.17 -7.75 8.97 0.38 1.01 -6.51 10.16 0.00 1.90 -7.31 10.68 0.00 3.06 -4.26 11.63 0.00
Leaf 61 0.19 -9.98 10.19 0.12 1.10 -7.00 9.67 0.00 2.10 -6.34 11.98 0.00 3.10 -5.49 11.71 0.00
Neck 4 Leaf 21 -0.10 -10.03 8.78 0.93 0.92 -7.07 10.15 0.00 2.05 -5.67 10.89 0.00 2.90 -4.51 11.47 0.00
Leaf 61 0.03 -8.27 10.03 0.76 1.20 -7.27 9.45 0.00 2.20 -7.28 9.33 0.00 3.10 -5.29 11.48 0.00
Neck 5 Leaf 21 0.08 -8.31 7.24 0.20 1.10 -6.95 8.68 0.00 1.90 -5.71 9.02 0.00 2.91 -3.51 13.13 0.00
Leaf 61 0.19 -6.15 6.82 0.37 1.05 -5.45 8.68 0.00 2.00 -4.39 8.52 0.00 3.00 -2.85 14.23 0.00
Unshifted 1mm Leaf Shift 2mm Leaf Shift 3mm Leaf Shift
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Table 21: Head & neck unshifted and central leaf shift position error – LVI data (mm) 
 
P-values are less than 0.05 for all shifted leaves for both LVI and RV data and medians fall close 
to their expected values; therefore we accept the alternative hypothesis that shifted leaf positions 
are distinguishable from planned leaf positions. Again, a false positive is seen in LVI data for 
neck case #2, leaf 21. 
Table 22 contains data for the head and neck case #5 systematic MLC shifts.  Again,   
these values are expected to be similar to the median errors found in the central leaf pair shifts. 
Table 22: Head and neck case #5 systematic MLC, range of median leaf errors (mm).  LVI (left); 
RV (right). 
 
The table shows that median leaf errors for systematic MLC shifts on head and neck case #5 
were close to the expected values of 0 mm, 1 mm and 3 mm for the corresponding shifts, 
verifying that single leaf shift detection methods can be applied to erroneous leaf groups for head 
and neck cases. 
Site Leaf # Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Neck 1 Leaf 21 -0.03 -8.54 9.43 0.64 1.01 -10.39 8.78 0.00 1.90 -7.72 10.05 0.00 3.00 -6.06 11.73 0.00
Leaf 61 0.10 -7.23 10.29 0.62 1.08 -10.09 10.53 0.00 2.08 -7.12 11.85 0.00 3.13 -7.89 12.91 0.00
Neck 2 Leaf 21 -0.10 -10.44 7.26 0.00 0.90 -10.02 7.73 0.00 1.90 -4.30 11.11 0.00 2.90 -5.03 10.83 0.00
Leaf 61 0.01 -7.55 9.12 0.55 1.00 -8.82 7.73 0.00 2.00 -4.49 12.23 0.00 3.09 -4.09 10.84 0.00
Neck 3 Leaf 21 0.00 -9.18 8.97 0.91 0.90 -6.51 10.16 0.00 1.95 -7.31 10.68 0.00 3.00 -4.26 11.63 0.00
Leaf 61 0.16 -9.98 10.19 0.06 1.04 -7.00 9.67 0.00 2.10 -6.34 11.98 0.00 3.10 -5.49 11.71 0.00
Neck 4 Leaf 21 -0.10 -10.03 8.78 0.32 1.00 -7.07 10.15 0.00 2.00 -5.67 10.89 0.00 2.95 -4.51 11.47 0.00
Leaf 61 0.02 -8.27 10.03 0.71 1.17 -8.08 9.45 0.00 2.05 -7.28 9.33 0.00 3.13 -5.29 11.48 0.00
Neck 5 Leaf 21 -0.02 -8.31 7.24 0.46 1.00 -8.30 8.68 0.00 1.94 -5.71 9.02 0.00 2.96 -3.51 13.13 0.00
Leaf 61 0.05 -6.15 6.82 0.56 1.00 -9.19 8.68 0.00 2.09 -6.00 8.52 0.00 3.03 -2.85 14.23 0.00
Unshifted 1mm Leaf Shift 2mm Leaf Shift 3mm Leaf Shift
Shift Bank Min Med Max
Unshifted Bank A -0.10 0.00 0.16
Bank B 0.02 0.11 0.20
1mm Shift Bank A 0.90 0.97 1.10
Bank B 0.98 1.13 1.20
3mm Shift Bank A 2.83 2.95 3.05
Bank B 3.00 3.10 3.18




Figure 25: Head and neck #5, 2° gantry error plans. RV (left) and LVI (right). 
Figure 25 shows head and neck case #5, 2° gantry error. For this delivery, median gantry 
errors for the RV and LVI, respectively, were 1.93° and 1.90° with ranges 1.40 to 2.75° and 0.45 
to 2.86°.  By applying the signed-rank test, we can verify that both the RV and LVI were capable 
of detecting a 2° systematic gantry error for head and neck case #5. Table 23 (RV) and  
Table 24 (LVI) contain average gantry errors for all gantry shift head and neck deliveries. 
Median errors correspond with shift values, and p-values for all shifted plans are less than 0.05; 
therefore these shifts are distinguishable. False positives are seen in case #4 and 5 for both 
recording systems and case #1 for the LVI system. 
Table 23: Head and neck gantry shifts – RV gantry error and p-values (degrees)  
 
 
Table 24: Head and neck gantry shifts – LVI gantry error and p-values (degrees) 
 
Site Med Min Max p Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Neck 1 -0.08 -2.17 1.51 0.09 1.01 -2.07 3.16 0.00 1.97 0.01 3.69 0.00 2.98 0.78 5.01 0.00 4.94 3.26 7.81 0.00
Neck 2 0.06 -3.62 2.93 0.14 0.97 -2.43 3.72 0.00 2.04 -1.68 4.40 0.00 3.00 -0.48 5.71 0.00 5.00 1.57 7.43 0.00
Neck 3 0.04 -2.06 1.01 0.89 0.96 -0.97 4.16 0.00 2.04 -0.31 4.62 0.00 3.01 0.92 4.65 0.00 5.04 1.75 6.80 0.00
Neck 4 0.08 -1.99 3.06 0.01 1.09 -1.03 2.08 0.00 2.06 -0.15 3.12 0.00 3.12 1.37 4.03 0.00 5.05 2.90 6.69 0.00
Neck 5 -0.13 -2.10 0.91 0.00 0.92 -1.16 2.10 0.00 1.93 1.40 2.75 0.00 2.91 1.00 3.71 0.00 4.89 2.85 6.21 0.00
Unshifted 1° Gantry Shift 2° Gantry Shift 5° Gantry Shift3° Gantry Shift
Site Med Min Max p Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Neck 1 -0.08 -2.17 2.30 0.00 0.98 -2.29 3.16 0.00 1.95 0.20 3.69 0.00 2.96 0.73 5.01 0.00 4.94 2.76 7.83 0.00
Neck 2 0.04 -3.92 2.93 0.05 1.00 -2.43 3.43 0.00 2.03 -1.68 4.60 0.00 3.02 -0.48 5.71 0.00 5.00 1.22 8.03 0.00
Neck 3 0.03 -2.18 2.15 0.74 0.99 -0.97 4.16 0.00 2.02 -0.38 4.68 0.00 3.00 0.92 4.65 0.00 5.01 1.42 6.80 0.00
Neck 4 0.06 -2.17 3.06 0.00 1.08 -1.03 2.21 0.00 2.08 -0.58 3.34 0.00 3.10 1.11 4.06 0.00 5.04 2.28 8.33 0.00
Neck 5 -0.09 -2.10 0.91 0.00 0.91 -1.16 2.49 0.00 1.90 0.45 2.86 0.00 2.91 0.90 3.88 0.00 4.90 2.81 6.27 0.00
Unshifted 1° Gantry Shift 2° Gantry Shift 3° Gantry Shift 5° Gantry Shift
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Table 25 contains resulting error detection values for both gantry and central leaf pair shifts. 
Table 25: Head and neck error detection table 
Case Leaf (RV) Gantry (RV) Leaf (LVI) Gantry (LVI) 
Neck 1 1 mm 1° 1 mm 1° 
Neck 2 1 mm 1° 1 mm 1° 
Neck 3 1 mm 1° 1 mm 1° 
Neck 4 1 mm 1° 1 mm 1° 
Neck 5 1 mm 1° 1 mm 1° 
Maximum 1 mm 1° 1 mm  1° 
 
We found that all head and neck cases were capable of detecting the 1 mm central leaf pair 
shift and 1° gantry shift using the Wilcoxon signed-rank test.  
Post-Mastectomy Chest Wall 
   
Figure 26: Chest #5, 1mm central leaf error delivery.  RV (left) and LVI (right). 
 
Figure 26 shows the average MLC leaf error recorded by the RV and LVI systems for a 
chest wall plan where a 1 mm error has been introduced in central leaf pair (leaves #21 and 61). 
Table 26 Table 21 show RV and LVI data, respectively, for median, minimum and maximum 
leaf errors and p-values for the unshifted and 1, 2, and 3 mm central leaf pair shift chest wall 
deliveries.  These errors compare leaf #21 and 61 recorded delivery positions against leaf #21 




Table 26: Chest wall unshifted and central leaf shift position error -- RV data (mm) 
 
Table 27: Chest wall unshifted and central leaf shift position error -- LVI data (mm) 
 
P-values are less than 0.05 for all shifted leaves for both LVI and RV data and medians fall close 
to their expected values; therefore we accept the alternative hypothesis that shifted leaf positions 
are distinguishable from planned leaf positions.  False positives are seen in RV data for case #1 
leaf 61 and LVI data for case #3 leaf 61. 
Table 28 contains data for the head and neck case #5 systematic MLC shifts.  Again,   
these values are expected to be similar to the median errors found in the central leaf pair shifts. 
Site Leaf # Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Chest 1 Leaf 21 0.06 -7.15 5.47 0.12 0.86 -8.63 6.90 0.00 1.96 -4.82 9.42 0.00 2.84 -4.62 9.42 0.00
Leaf 61 0.20 -5.75 6.85 0.01 1.12 -6.31 8.51 0.00 2.10 -5.25 12.27 0.00 2.79 -5.25 12.27 0.00
Chest 2 Leaf 21 -0.10 -11.26 7.66 0.32 0.90 -9.11 9.46 0.00 1.88 -5.01 8.96 0.00 2.84 -4.01 11.12 0.00
Leaf 61 0.00 -6.69 10.56 0.53 1.05 -7.44 9.86 0.00 2.08 -8.96 9.79 0.00 3.03 -4.72 11.61 0.00
Chest 3 Leaf 21 0.12 -7.96 6.29 0.24 1.23 -7.68 10.32 0.00 1.90 -5.42 14.52 0.00 2.90 -3.74 10.72 0.00
Leaf 61 0.08 -7.96 5.45 0.55 1.02 -7.58 9.65 0.00 2.00 -5.22 8.28 0.00 3.10 -2.70 9.08 0.00
Chest 4 Leaf 21 0.01 -7.85 8.40 1.00 0.80 -5.13 11.58 0.00 2.04 -7.02 9.39 0.00 3.17 -5.91 11.30 0.00
Leaf 61 0.20 -10.00 8.00 0.31 1.04 -4.46 11.28 0.00 2.17 -7.42 10.60 0.00 3.10 -5.02 11.83 0.00
Chest 5 Leaf 21 -0.16 -7.89 8.06 0.27 0.96 -8.83 6.95 0.00 1.67 -2.34 7.99 0.00 2.84 -4.39 9.36 0.00
Leaf 61 -0.06 -7.76 9.16 0.67 1.12 -8.33 9.49 0.00 1.76 -3.99 11.96 0.00 2.99 -4.93 10.49 0.00
Unshifted 1mm Leaf Shift 2mm Leaf Shift 3mm Leaf Shift
Site Leaf # Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Chest 1 Leaf 21 0.00 -7.15 8.03 0.07 0.93 -8.63 6.93 0.00 2.00 -8.22 9.42 0.00 2.38 -3.75 9.19 0.00
Leaf 61 0.19 -5.75 7.83 0.11 1.18 -6.31 8.51 0.00 2.08 -9.35 12.27 0.00 3.13 -4.32 8.23 0.00
Chest 2 Leaf 21 -0.03 -11.26 7.66 0.61 0.90 -9.11 9.46 0.00 1.90 -5.01 12.53 0.00 2.90 -4.01 11.12 0.00
Leaf 61 0.10 -6.69 10.56 0.05 1.10 -7.44 9.86 0.00 2.12 -8.96 9.79 0.00 3.10 -4.72 11.61 0.00
Chest 3 Leaf 21 -0.05 -7.50 7.21 0.59 0.90 -7.68 10.32 0.00 1.95 -5.42 14.52 0.00 2.90 -3.74 10.72 0.00
Leaf 61 0.10 -7.60 7.32 0.01 1.05 -7.58 9.65 0.00 2.10 -5.22 12.14 0.00 3.10 -2.70 9.91 0.00
Chest 4 Leaf 21 -0.10 -10.99 6.08 0.81 0.90 -5.13 11.58 0.00 1.92 -6.45 9.39 0.00 2.96 -5.91 11.30 0.00
Leaf 61 0.06 -9.10 5.47 0.77 1.09 -4.46 11.28 0.00 2.09 -5.72 10.60 0.00 3.06 -5.02 11.83 0.00
Chest 5 Leaf 21 -0.10 -7.89 8.06 0.08 0.86 -8.83 6.96 0.00 1.93 -2.22 7.99 0.00 2.94 -4.39 9.36 0.00
Leaf 61 0.00 -9.01 9.16 0.74 1.10 -8.33 9.49 0.00 2.02 -3.99 11.96 0.00 3.10 -4.93 10.49 0.00




Table 28: Chest wall case #5 systematic MLC shift, range of median leaf errors (mm).  LVI 
(left); RV (right). 
 
The table shows that median leaf errors for systematic MLC shifts on chest wall case #5 
were close to the expected values of 0 mm, 1 mm and 3 mm for the corresponding shifts, 
verifying that single leaf shift detection methods can be applied to erroneous leaf groups for 
chest wall cases. 
 
Figure 27: Chest wall #5, 2° gantry error plans. RV (left) and LVI (right). 
 
 
Figure 27 shows chest wall case #5, 2° gantry error. For this delivery, median gantry errors 
for the RV and LVI, respectively, were 1.96° and 1.99° with ranges -0.03 to 4.58° and -0.24 to 
3.53°.  By applying the signed-rank test, we can verify that both the RV and LVI were capable of 
detecting a 2° systematic gantry error for chest wall case #5. Table 29 (RV) and Table 30 (LVI) 
contain average gantry errors for all gantry shift chest wall deliveries. Median errors correspond 
Shift Bank Min Med Max
Unshifted Bank A -0.21 -0.13 0.11
Bank B -0.11 0.03 0.17
1mm Shift Bank A 0.80 0.90 1.10
Bank B 0.79 1.18 1.31
3mm Shift Bank A 2.77 2.88 3.10
Bank B 2.97 3.11 3.21
Chest 5 Systematic MLC shift error (mm) - RV
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with shift values, and p-values for all shifted plans are less than 0.05; therefore these shifts are 
distinguishable. A false positive is seen in LVI data for case #2. 
Table 29: Chest wall gantry shifts – RV gantry error and p-values (degrees) 
 
 
Table 30: Chest wall gantry shifts – LVI gantry error and p-values (degrees) 
 
Table 31 contains resulting error detection values for both gantry and central leaf pair shifts. 
Table 31: Chest wall error detection table 
Case Leaf (RV) Gantry (RV) Leaf (LVI) Gantry (LVI) 
Chest 1 1 mm 1° 1 mm 1° 
Chest 2 1 mm 1° 1 mm 1° 
Chest 3 1 mm 1° 1 mm 1° 
Chest 4 1 mm 1° 1 mm 1° 
Chest 5 1 mm 1° 1 mm 1° 
Maximum 1 mm 1° 1 mm  1° 
 
We found that all chest wall cases were capable of detecting the 1 mm central leaf pair shift 
and 1° gantry shift using the Wilcoxon signed-rank test.  
3.2.2 Largest values for each site taken as minimum detectable error (LVI and RV) 
Table 32: Minimum detectable errors for prostate, head and neck, and chest wall cases 
Site Leaf (RV) Gantry (RV) Leaf (LVI) Gantry (LVI) 
Prostate 1 mm 1° 1 mm  1° 
Head and neck 1 mm 1° 1 mm 1° 
Chest Wall 1 mm 1° 1 mm  1° 
 
Site Med Min Max p Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Chest 1 0.00 -1.21 1.83 0.38 0.89 -0.43 3.67 0.00 1.95 0.98 4.16 0.00 3.00 1.89 4.91 0.00 4.93 3.73 7.17 0.00
Chest 2 -0.05 -1.79 1.34 0.08 0.91 -0.63 2.87 0.00 1.95 0.71 3.77 0.00 2.91 1.18 5.21 0.00 4.93 3.46 5.75 0.00
Chest 3 -0.05 -1.34 1.58 0.59 1.03 -0.20 2.45 0.00 1.98 -0.08 4.09 0.00 -- -- -- -- -- -- -- --
Chest 4 -0.03 -1.08 1.07 0.30 1.00 -0.08 1.90 0.00 1.95 0.68 4.28 0.00 3.01 1.57 4.41 0.00 4.97 3.90 6.08 0.00
Chest 5 -0.06 -1.33 0.88 0.16 0.96 -0.35 2.48 0.00 1.96 -0.03 4.58 0.00 2.95 0.86 5.16 0.00 5.01 3.14 5.84 0.00
Unshifted 1° Gantry Shift 2° Gantry Shift 3° Gantry Shift 5° Gantry Shift
Site Med Min Max p Med Min Max p Med Min Max p Med Min Max p Med Min Max p
Chest 1 0.00 -1.42 1.55 0.97 0.95 -0.43 3.67 0.00 1.99 -0.24 4.73 0.00 3.00 1.70 4.91 0.00 4.99 3.57 7.42 0.00
Chest 2 -0.09 -2.26 1.20 0.00 0.92 -1.13 2.87 0.00 1.93 0.07 3.79 0.00 2.90 1.08 5.21 0.00 4.91 3.46 6.13 0.00
Chest 3 0.00 -1.21 0.97 0.61 1.00 -1.36 2.55 0.00 1.95 -0.08 4.09 0.00 -- -- -- -- -- -- -- --
Chest 4 -0.02 -1.34 0.00 0.98 1.03 -0.29 2.07 0.00 1.99 0.65 4.32 0.00 3.00 1.57 4.41 0.00 5.00 3.90 6.17 0.00
Chest 5 -0.01 -1.41 0.00 0.25 0.97 -1.00 2.48 0.00 1.99 -0.24 3.53 0.00 2.94 0.86 5.29 0.00 5.00 3.14 7.01 0.00
5° Gantry ShiftUnshifted 1° Gantry Shift 2° Gantry Shift 3° Gantry Shift
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To select minimum detectable errors, we chose the largest error detection values.   Our 
system should be capable of handling a variety of plans, and by using the largest values we 
achieve the most conservative estimate of our systems’ error detection capability.  Both systems 
(LVI and RV) performed about equally for all cases, and minimum detectable errors were the 
same for each error type and site. For all sites, the 1 mm central leaf error and the 1° gantry error 
were detectable.   
3.3 Aim 3 Results 
3.3.1 Formulate gamma pass-rate table (LVI and RV) 
 For Aim 3, planar dose profiles for original plans were calculated within the treatment 
planning system, and these profiles were used as a benchmark to assess delivery fidelity. Tables 
showing the agreement between planned, RV-reconstructed, or LVI-reconstructed doses with the 
measured doses are shown below. Agreement was assessed by computing the percentage of 
points passing the gamma criteria at 3% dose difference and 3 mm distance to agreement; and at 
2%/2mm gamma criteria.  Table 33 and Table 34 show the agreement for prostate cases at 
3%/3mm and 2%/2mm respectively. We would expect to see improved agreement for 
reconstructed dose distributions, however in many cases this does not hold true.  In prostate 
cases #1, 4, and 5 there are slight improvements for the 3%/3mm gamma criteria for both RV- 
and LVI-reconstructions. Additionally, tables showing the improvement in agreement in the 
reconstructed dose over the planned dose at the 3%/3mm gamma criteria level are provided.  
Dose agreement improvement was quantified with the Wilcoxon signed-rank test, and p-values 
of less than 0.05 were required to conclude statistically significant improvement. 
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Table 33: Prostate MapCheck agreement (%) (3%/3mm gamma) 
Planar Dose Prostate 1 Prostate 2 Prostate 3 Prostate 4 Prostate 5 
Planned 95.7 98.7 95.1 95.7 98.5 
RV 97.6 97.6 93.4 97.9 99.2 
LVI 97.1 98.6 96.8 96.0 99.4 
 
 
Table 34: Prostate MapCheck agreement (%) (2%/2mm gamma) 
Planar Dose Prostate 1 Prostate 2 Prostate 3 Prostate 4 Prostate 5 
Planned 87.6 92.1 87.0 81.8 93.9 
RV 89.7 86.3 81.8 88.4 96.7 
LVI 91.0 90.8 87.9 81.8 95.0 
 
Table 35: Prostate MapCheck agreement improvement (%) (3%/3mm gamma) 
Planar Dose Prostate 1 Prostate 2 Prostate 3 Prostate 4 Prostate 5 p-value 
RV-Planned 1.9 -1.1 -1.7 2.2 0.7 0.63 
LVI-Planned 1.4 -0.1 1.7 0.3 0.9 0.13 
 
Table 35 shows the improvement in agreement of the reconstructed dose over the planned 
dose. For prostate cases, RV-reconstruction yielded a p-value of 0.63 and LVI-reconstruction 
yielded a p-value of 0.13.  Therefore, both RV- or LVI-reconstructions failed to show 
statistically significant improvement in the dose distribution.   
Table 36 and Table 37 show results for 3%/3mm and 2%/2mm head and neck agreement. 
Table 38 shows head and neck agreement improvements. 
Table 36: Head and neck MapCheck agreement (%) (3%/3mm gamma) 
Planar Dose Neck 1 Neck 2 Neck 3 Neck 4 Neck 5 
Planned 99.3 94.4 97.3 99.2 98.5 
RV 98.3 93.5 98.4 97.9 96.5 
LVI 99.3 95.3 98.5 99.0 98.0 
 
Table 37: Head and neck MapCheck agreement (%) (2%/2mm gamma) 
Planar Dose Neck 1 Neck 2 Neck 3 Neck 4 Neck 5 
Planned 95.0 84.7 88.7 95.6 90.3 
RV 93.7 86.2 90.1 92.9 86.9 




Table 38: Head and neck MapCheck agreement improvement (%) (3%/3mm gamma) 
Planar Dose Neck 1 Neck 2 Neck 3 Neck 4 Neck 5 p-value 
RV-Planned -1.0 -0.9 1.1 -1.3 -2.0 0.31 
LVI-Planned 0.0 0.9 1.0 -0.2 -0.5 0.63 
 
Table 38 shows the improvement in agreement of the reconstructed dose over the planned 
dose. For head and neck cases, RV-reconstruction yielded a p-value of 0.31 and LVI-
reconstruction yielded a p-value of 0.63.  Therefore, both RV- or LVI-reconstructions failed to 
show statistically significant improvement in the dose distribution.   
 
Table 39 and Table 40 show results for 3%/3mm and 2%/2mm chest wall agreement. Table 
41 shows chest wall agreement improvements with p-values. 
Table 39: Chest wall MapCheck agreement (%) (3%/3mm gamma) 
Planar Dose Chest 1 Chest 2 Chest 3 Chest 4 Chest 5 
Planned 99.3 85.0 98.6 95.3 96.8 
RV 98.3 78.0 97.0 93.0 93.6 
LVI 99.3 84.0 98.5 95.0 96.1 
 
 
Table 40: Chest wall MapCheck agreement (%) (2%/2mm gamma) 
Planar Dose Chest 1 Chest 2 Chest 3 Chest 4 Chest 5 
Planned 96.3 67.0 95.4 84.1 89.5 
RV 93.4 61.7 88.3 78.1 83.5 
LVI 95.5  65.4 93.5 81.8 87.1 
 
Table 41: Chest wall MapCheck agreement improvement (%) (3%/3mm gamma) 
Planar Dose Chest 1 Chest 2 Chest 3 Chest 4 Chest 5 p-value 
RV-Planned -1.0 -7.0 -1.6 2.3 -3.2 0.31 
LVI-Planned 0.0 -1.0 -0.1 -0.3 -0.7 0.13 
 
Table 41 shows the improvement in agreement of the reconstructed dose over the planned 
dose. For prostate cases, RV-reconstruction yielded a p-value of 0.31 and LVI-reconstruction 
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yielded a p-value of 0.13.  Therefore, both RV- or LVI-reconstructions failed to show 
statistically significant improvement in the nominal dose distribution.   
3.3.2 Systematic MLC Shifts 
To further test the ability of the recording system, we reconstructed and compared 3 mm 
systematic MLC shifted deliveries for prostate case #5, head and neck case #5, and chest wall 
case #5.  In these cases, the original unshifted plan’s planar dose profile is compared against the 
shifted delivery measurement, whereas the RV- and LVI-reconstructions are based on the shifted 
delivery data.   
Table 42 and Table 43 show results for 3%/3mm and 2%/2mm agreement for these three 
deliveries. 
Table 42: 3 mm systematic MLC shift MapCheck agreement (%) (3%/3mm gamma) 
Planar Dose Prostate 5 Neck 5 Chest 5 Average 
Planned 95.8 89.8 91.1 92.2 
RV 99.8 97.2 95.1 97.4 
LVI 99.8 98.7 97.7 98.7 
 
Table 43: 3mm systematic MLC shift MapCheck agreement (%) (2%/2mm gamma) 
Planar Dose Prostate 5 Neck 5 Chest 5 Average 
Planned 89.5 81.2 79.4 83.4 
RV 98.3 91.0 86.1 91.8 
LVI 97.9 93.8 89.2 93.6 
 
In all three cases, the RV- and LVI-reconstructions significantly improve agreement. The 
difference is most clearly visible in the average columns at the far right.  The signed-rank test 
was not applied here because for small sample sizes, statistical significance cannot be determined 
at a 95% confidence level. 
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3.3.3 Measurement reproducibility 
Head and neck case 1 was delivered three times to verify reproducibility of Aim 3 methods.  
Results for 3%/3mm agreement and 2%/2mm agreement are shown in Table 44 and Table 45. 
Table 44: Head and neck runs 1-3 MapCheck agreement (3%/3mm gamma criteria) 
Planar Dose Run 1 Run 2 Run 3 
Original 99.3 98.4 98.3 
RV 98.3 98.8 98.7 
LVI 99.3 98.7 99.2 
 
Table 45: Head and neck runs 1-3 MapCheck agreement (2%/2mm gamma criteria) 
Planar Dose Run 1 Run 2 Run 3 
Original 95.0 92.7 91.8 
RV 93.7 92.9 92.2 
LVI 94.5 92.8 93.4 
 
The data show consistency in measurement agreement between runs for the original, RV-
reconstructed, and LVI-reconstructed planar dose comparisons.   
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Chapter 4: Discussion & Conclusions 
4.1 Summary of findings 
In this study, we evaluated the ability of a treatment delivery verification system to detect 
clinically significant mechanical errors in VMAT delivery utilizing data contained within a 
commercial record and verify (RV) system, and tested whether the system can be used to 
reconstruct dose distributions that agree more closely with measured dose distributions than do 
the original treatment plans.  To achieve this, five prostate, five head and neck and five post-
mastectomy chest-wall VMAT treatment plans were delivered and measured with a diode array 
while delivery data were recorded. 
Mechanical error thresholds were found to be 1 mm for systematic MLC error and 2° for 
systematic gantry error.  By applying signed-rank tests to delivery data error, we found that both 
systems were capable of detecting 1 mm MLC error and 1° at a 95% confidence level, as all p-
values were less than 0.05.  Because the system is capable of detecting errors at the threshold 
levels, we conclude that the delivery verification system is capable of detecting clinically 
significant mechanical errors in VMAT delivery.   
We found that dose reconstructed using the recorded delivery parameters showed no 
significant improvement in agreement with measured values, as p-values were consistently 
greater than 0.05.  Thus, while the delivery verification system can detect mechanical errors, it 
cannot more accurately estimate of the daily delivered dose than the original plans do. However, 
the systematic MLC shift delivery data show that for significantly erroneous plans, the delivery 





4.2 Aim 1 Discussion 
The goal of Aim 1 was to examine the sensitivity of VMAT plans to mechanical errors of 
the gantry and MLC of three anatomical sites: prostate, head and neck and post-mastectomy 
chest wall. This was accomplished by inserting simulated errors into plan files and recalculating 
the modified dose distributions within the TPS.  We found that systematic shifts of the MLC 
produced the greatest dosimetric change, corresponding to lower position thresholds for that 
error type. This finding is consistent with previous work of Oliver M (2011) and Tatsimi, et al. 
(2010).  Oliver et al. (2011) found that a systematic MLC shift could decrease prostate PTV dose 
by about 1% per mm and head and neck PTV dose by about 3.6 Gy per mm for a 70 Gy 
prescription.  Tatsumi et al. (2011) found a systematic MLC shift action level of 0.8 mm, which 
is similar to our systematic MLC shift threshold of 1 mm. 
Two types of random MLC shifts were also examined: uniformly-distributed and Gaussian-
distributed random shifts.  Plans tended to be more sensitive to Gaussian-distributed random 
shifts, and this can be explained by the fact that statistical distribution of a Gaussian function of 
sigma x will produce larger MLC errors on average than the uniform. The expected average 
absolute error for a uniform-random MLC shift with a maximum shift of 1 cm is 5.0 mm, 
whereas the expected average absolute error for a Gaussian-random MLC shift with σ = 1 cm is 
about 6.8 mm. 
Central leaf pair errors produced the least dosimetric change, which is expected since fewer 
leaves are shifted from their planned positions.  The effect of central leaf pair error was smallest 
in chest wall cases, which is due to the relatively large size of chest wall fields that require more 
leaves be utilized for planning and delivery. 
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The influence of gantry errors on the planned dose was found to be site-dependent. Head 
and neck plans were more sensitive than prostate plans, as indicated by the minimum error 
thresholds. We believe this to be due to the geometry of the target volumes.  The prostate is a 
small, centrally located and roughly spherical in shape.  This spherical symmetry suggests that 
gantry error should have a smaller effect on the PTV dose -- a perfectly symmetric geometry 
would nullify the effect of gantry error. In head & neck and chest wall cases, the PTV is not 
centrally located or symmetric and therefore the plan is more susceptible to errors in gantry 
positioning. Table 46 summarizes the error thresholds determined in this work. 











Prostate 1 mm 2 mm 3 mm  5 mm 5° 
Head and neck 1 mm 3 mm 5 mm  3 mm 2° 
Chest Wall 3 mm 5 mm 5 mm  10 mm 3° 
Global Minimum 1 mm 2 mm 3 mm 3 mm 2° 
 
These thresholds represent minimum shifts producing clinically unacceptable changes in 
dose distributions, and should be detectable by the delivery verification system. Since a 1 mm 
systematic MLC shift was found to significantly degrade dose distributions in some cases, an 
effective delivery verification system should be capable of detecting a 1 mm leaf shift to ensure 
detection of dosimetrically meaningful errors.  Similarly, since the minimum gantry error 
threshold was found to be 2°, a 2° gantry shift must be detectable. 
4.3 Aim 2 Discussion 
The purpose of aim 2 was to establish the minimum detectable leaf and gantry errors, as the 
usefulness of the LVI and RV systems is dependent on their ability to detect errors at or below 
the level of the Aim 1 thresholds.   This was accomplished by delivering select shifted plans 
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while both the RV system and the LVI system recorded delivery parameters, and analyzing leaf 
and gantry delivery errors.   
For leaf errors, central leaf pair shifts of magnitude 1, 2, and 3 mm were delivered for each 
case, and systematic MLC shifts of magnitude 1 and 3 mm were delivered for one prostate, one 
head and neck, and one chest wall case.  For central leaf pair shifts, all p-values were less than 
0.05, meaning that all shifts were detectable.  The systematic MLC shift median errors agreed 
with expected values, verifying that the single leaf error detection method can be applied to 
systematic MLC error. Since leaf errors were detectable at a 1 mm level for both LVI and RV 
systems and this was the minimum mechanical error threshold for systematic MLC shifts, we are 
assured that our system is capable of detecting dosimetrically meaningful MLC errors.  P-values 
less than 0.05 were also found for unshifted deliveries, however, and because used a 95% 
confidence level to determine error detectability, some of the unshifted plans were falsely 
categorized as erroneous.   
For gantry errors, gantry shifts of magnitude 1, 2, 3, and 5° were delivered for each case.  
All gantry error p-values were less than 0.05, meaning that all shifts were detectable.  Since 
gantry errors were detectable at a 1° level for both LVI and RV systems and the mechanical error 
threshold for gantry error was actually 2°, we are assured that our system is easily capable of 
detecting dosimetrically meaningful gantry errors.  In some cases, unshifted delivery gantry 
errors also showed p-values of less than 0.05. 
Both LVI and RV systems demonstrate slightly erratic recording of delivery data due to the 
latency in the iCom-Vx data stream, which, when combined with MU-indexing linear 
interpolation error can occasionally result in relatively large errors (up to 5-10 mm in leaf 
position and up to a few degrees in gantry angle).  The error makes it impossible to distinguish 1 
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mm leaf and 2° gantry errors on a per-control-point basis.  This has implications for Aim 3, but 
we can still identify significant delivery error by analyzing the distribution of errors over the 
course of delivery. 
4.4 Aim 3 Discussion 
The purpose of Aim 3 was to determine whether the RV system can be used to reconstruct 
dose distributions that agree more closely with measured dose distributions than do the original 
treatment plans. This was accomplished by delivering the fifteen selected plans while recording 
delivery data and measuring the dose distribution with a diode array, and finally comparing 
agreement using the SNC Patient software.  We found RV-reconstructed and LVI-reconstructed 
dose profiles by reimporting delivery data to the TPS and recalculating planar dose profiles.  By 
comparing these profiles with MapCHECK measurements, we determined the effectiveness of 
delivery-data based dose reconstruction.   
Aim 3 results show insignificant improvement in reconstructed dose distributions for both 
LVI and RV data.  P-values are greater than 0.05 in all cases using a 3%/3mm gamma criteria, 
meaning that the agreement between the original plan planar dose with measurement was not 
significantly different than the agreement between reconstructed planar dose and measurement. 
Our inability to improve dose agreement by delivery reconstruction can be attributed to a 
few factors.  First, as mentioned earlier, latency error can cause large individual leaf and gantry 
errors.  Since the TPS calculates planar dose profiles on a per-control-point basis, this can result 
in significant error in the overall computed dose profile.  Additionally, phantom setup error and 
detector array error cause uncertainty in measured dose profiles which will variably affect 
agreement with both reconstructed and planned dose profiles.  Residual uncertainty in the TPS 
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model and limitations in dose calculation algorithms contribute to uncertainty in planar dose 
profiles. 
When it was found that improvements in agreement could not be demonstrated with nominal 
plans, we delivered shifted plans.  We delivered 3 mm systematic-MLC shift plans for prostate 
case #5, head and neck case #5, and chest wall case #5 in an effort to determine whether 
reconstructing an intentionally erroneous plan could improve agreement.  Unfortunately the 
Wilcoxon signed-rank test does not provide the statistical power required to distinguish 
differences for such a small sample size, but RV- and LVI-reconstruction demonstrated 
significant improvement in the three cases studied.  Based on this, we conclude that both systems 
are capable of improving agreement for significantly erroneous deliveries. 
4.5 Limitations 
One limitation of the project was the range of sites tested.  While prostate, head and neck 
and chest wall patients are common VMAT candidates, other sites including lung, pelvis and 
abdomen also utilize VMAT.  To apply our system to other sites, a set of cases from each site 
should be tested to determine error thresholds and detectability. 
Our project tested only five different error types, including systematic and random MLC 
shifts and systematic gantry shifts.  Previous studies examined other errors in addition to these, 
including two significant error types not included in this work: MLC gap close and MLC gap 
open (Oliver M 2011, Oliver, et al. 2010).  Since these two error types were previously shown to 
produce significant dosimetric effect, it would be interesting and useful to see the effect of this 
error on the fifteen cases studied here. Additionally, since only a finite number of error 
magnitudes could be examined, error thresholds and detectability levels are fairly coarse.  Our 
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project only examined error magnitudes of 1, 2, 3, 5 and 10 mm/°, but it could be useful to 
analyze errors at a 0.5 mm/° interval or less. 
The Wilcoxon signed-rank test yielded a fairly large number of false positives. For the RV 
data, 4 out of 15 gantry positions and 4 out of 30 unshifted leaves incorrectly tested as erroneous 
and for the LVI these values increased to and 7 out of 15 and 9 out of 30, respectively.  The 
increased false positive count for the LVI system can be explained by the larger number of data 
points recorded per delivery, as larger sample sizes give the signed-rank test increased power and 
increased liability to return false positives. The reliability of the system is limited by these false 
positives, as accurate deliveries will sometimes be incorrectly flagged as erroneous.  
Modification of comparison methods could help to lessen the frequency of these false positives. 
The inherent iCom-Vx data error limited the accuracy of our delivery verification system.  
As described earlier, it is still possible to distinguish errors over the course of delivery, but 
individual leaf and gantry positions at each control point are unreliable.  This error limited the 
ability of the RV and LVI systems’ abilities to accurately reconstruct planar dose profiles, and 
such reconstructions could be significantly improved with a more accurate data stream. 
Finally, while examining individual errors can be useful, true deliveries exhibit a 
combination of both systematic and random MLC and gantry errors.  Since there are infinite 
possibilities for error combinations, the best approximation is to simulate specific error types 
individually. 
4.6 Future Work 
Future work could include expanding the number of cases, range of sites, and range of error 
types and magnitudes studied. Sites of interest include lung, abdomen, and pelvis and error types 
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of interest include MLC gap-open and MLC gap-close.  Error magnitudes could be expanded to 
include 1.5, 2.5 and 4 mm/° to improve error threshold and detectability resolution. 
 By modifying the signed-rank test confidence level requirement, it might be possible to 
reduce the number of false positives while maintaining the ability to detect true errors.  Another 
approach could be to combine the rank test with a median or average error threshold, as all 
median values reported were within 0.2 to 0.3 mm of expectation. 
Clinical implementation of the RV-based system would simply require an automated 
script to extract delivery data from the RV system using an existing SQL database query module. 
The script would then compute MLC and gantry errors for each delivery, and could be 
programmed to notify the user when mechanical tolerances have been exceeded.  The LVI-based 
system is currently impractical for clinical implementation.  The third party software can be 
unstable, and unintentional program terminations also sever iCom communications, which 
requires the RV system be rebooted.  If the instability issue could be solved, the program could 
be configured to send data to a remote terminal where errors would be computed and analyzed. 
 One significant issue with the current system is the latency in the iCom-Vx data stream.  
If another method could be developed for extracting data directly from the treatment control 
system, there is potential for improvement in delivery data accuracy, which would improve both 
error detection and delivery reconstruction.  Currently, extracting TCS data requires service 
mode delivery, with active data logging.  If a module could be developed for automatic 
collection of delivery data in clinical mode, TCS data from each patient treatment could be 
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Appendix A: Aim 1 Results 
 
          





          






          






          






          





         






         




         





         





         





         






         




         





         





         






         






         




         





         





         






         






         




         





         





         






         






         




         





         





         






         






         




         





         





         






         






         




         





         





         






         






         




         





         





         






         






         




         





         





         






         






         




         





         





         




         






         




         





         





         





         






         




         





         





         






         






         




         





         





         






         






         




         





         





         
























































































































































































































































































































































Appendix C: Aim 3 Results 
 





Figure 134: Prostate 1 RV-reconstructed MapCHECK agreement 
 





Figure 136: Prostate 2 Original Plan MapCHECK Agreement 
 





Figure 138: Prostate 2 LVI-reconstructed MapCHECK Agreement 
 





Figure 140: Prostate 3 RV-reconstructed MapCHECK Agreement 
 
 





Figure 142: Prostate 4 Original Plan MapCHECK Agreement 
 
 





Figure 144: Prostate 4 LVI-reconstructed MapCHECK Agreement 
 
 





Figure 146: Prostate 5 RV-reconstructed MapCHECK Agreement 
 
 





Figure 148: Neck 1 Original Plan MapCHECK Agreement 
 





Figure 150: Neck 1 LVI-reconstructed MapCHECK Agreement 
 
 





Figure 152: Neck 2 RV-reconstructed MapCHECK Agreement 
 
 





Figure 154: Neck 3 Original Plan MapCHECK Agreement 
 





Figure 156: Neck 3 LVI-reconstructed MapCHECK Agreement 
 
 





Figure 158: Neck 4 RV-reconstructed MapCHECK Agreement 
 
 





Figure 160: Neck 5 Original Plan MapCHECK Agreement 
 





Figure 162: Neck 5 LVI-reconstructed MapCHECK Agreement 
 





Figure 164: Chest 1 RV-reconstructed MapCHECK Agreement 
 





Figure 166: Chest 2 Original Plan MapCHECK Agreement 
 





Figure 168: Chest 2 LVI-reconstructed MapCHECK Agreement 
 





Figure 170: Chest 3 RV-reconstructed MapCHECK Agreement 
 





Figure 172: Chest 4 Original Plan MapCHECK Agreement 
 





Figure 174: Chest 4 LVI-reconstructed MapCHECK Agreement 
 





Figure 176: Chest 5 RV-reconstructed MapCHECK Agreement 
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